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Background: Biologic therapies can be highly effective for the treatment of severe psoriasis but 
response for individual patients can vary according to drug. Predictive biomarkers to guide 
treatment selection could improve patient outcomes and treatment cost-effectiveness. 
Objective: We sought to test whether HLA-C*06:02, the primary genetic susceptibility allele for 
psoriasis, predisposes patients to respond differently to the two most commonly prescribed 
biologics for psoriasis, adalimumab (anti-TNFα) and ustekinumab (anti-IL12/23). 
Methods: The study utilises a national psoriasis registry that includes longitudinal treatment and 
response observations and detailed clinical data. HLA alleles were imputed from genome-wide 
genotype data for 1,326 patients for whom PASI90 response status (90% reduction in psoriasis area 
and severity index) was observed after 3, 6 or 12 months of treatment. We developed regression 
models of PASI90 response, examining the interaction between HLA-C*06:02 and drug type 
(adalimumab or ustekinumab) while accounting for potentially confounding clinical variables. 
Results: HLA-C*06:02 negative patients were significantly more likely to respond to adalimumab 
than ustekinumab at all time-points (most strongly at 6m: odds ratio (OR) = 2.95, P = 5.85×10
-7
) and 
the difference was greater in HLA-C*06:02 negative patients with psoriatic arthritis (PsA; OR = 5.98, 
P = 6.89×10
-5
). Biologic naive patients that were HL -C*06:02 positive and PsA negative 
demonstrated significantly poorer response to adalimumab at 12m (OR = 0.31, P = 3.42×10
-4
). 
Results from HLA-wide analyses were consistent with HLA-C*06:02 itself being the primary effect 
allele. We found no evidence for genetic interaction between HLA-C*06:02 and ERAP1. 
Conclusion: This large observational study suggests that reference to HLA-C*06:02 status could offer 
substantial clinical benefit when selecting treatments for severe psoriasis. 
 
Clinical Implications 
HLA-C*06:02 is associated with differential response to adalimumab and ustekinumab in psoriasis 
patients. Together with psoriatic arthritis status, HLA-C*06:02 status could inform optimal selection 
















In a large observational study, psoriasis patients lacking the susceptibility allele HLA-C*06:02 
demonstrate significantly better response to adalimumab than ustekinumab. The effect is stronger 
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Psoriasis is a chronic immune-mediated skin disease with a prevalence of up to 3% in developed 
nations
1
. It is responsible for a high global burden of disability
2
 and the economic impact, in the 
United States alone, runs into the tens of billions of dollars
3
. Psoriasis is caused by a complex 
interplay of genetic and environmental factors not yet fully understood
4, 5
, and molecular genetic 




In recent years the clinical management of psoriasis has been revolutionised by a series of 
highly effective monoclonal antibody therapies
8
. The most widely adopted of these biologics include 
adalimumab, which targets TNFα, and ustekinumab, which targets the p40 subunit common to IL-12 
and IL-23 and thus inhibits downstream IL-17 signalling. Clinical trials demonstrate that 71% of 
moderate to severe psoriasis patients achieve a 75% reduction in psoriasis area and severity index 
(PASI75 response) after 16 weeks of adalimumab treatment, with 45% achieving the superior PASI90 
response that is consistent with being “clear” or “nearly clear” of disease
9
. Similarly, ustekinumab 
induces a PASI75 response within 12 weeks for 67% of patients, and PASI90 response for 39% across 
dosing groups
10
. British Association of Dermatologists (BAD) guidelines recommend that in the 
absence of relevant contraindications both drugs should be considered equally as first-line biologic 
therapy for psoriasis, unless active psoriatic arthritis (PsA) is present in which case adalimumab is 
preferred
11




Since individuals can respond differently to different biologics, there is great potential to 
improve patient outcomes and optimise use of these expensive therapies
13
 through the 
identification of biomarkers that can inform which therapies are most likely to be efficacious. The 
MHC class I allele HLA-C*06:02 is a promising candidate biomarker. HLA-C*06:02 is the genetic 
variant that makes the largest contribution to psoriasis susceptibility: it accounts for more than 6% 
of variance in disease risk
14
 and each copy of the HLA-C*06:02 allele carried increases an individual’s 
risk of psoriasis five-fold
15
. Its effect is modified by an interaction with genetic variants in the gene 
ERAP1, which encodes a peptide-trimming protein involved in MHC antigen presentation
15
. 
HLA-C*06:02 status has also been reported to be associated with differences in clinical presentation 
of psoriasis, with HLA-C*06:02 positive patients experiencing earlier onset, differences in lesion 
severity and distribution, higher incidence of the Koebner phenomenon and increased likelihood of 
exacerbation due to streptococcal throat infection
16-18
. These differences hint at distinct 
pathophysiologies and differential response to treatment might therefore be expected. Some 















to ustekinumab among HLA-C*06:02 positive patients than among HLA-C*06:02 negative patients
19-
21
. The relationship between HLA-C*06:02 and response to anti-TNF agents is unclear
22
. 
With the aim of improving outcomes in individuals with moderate to severe psoriasis we 
therefore sought to test the hypothesis that HLA-C*06:02 status is an effective predictive biomarker 
of response that could be used to inform treatment selection between the two most commonly used 
biologics, adalimumab and ustekinumab. As such, we have undertaken a retrospective evaluation of 
HLA-C*06:02 as a predictive biomarker in a large prospective observational study of biologic 
interventions in the UK psoriasis population. Our primary definition of positive treatment response is 
achievement of PASI90, as it correlates with the clinically important status of “clear” or “nearly 
clear” of psoriasis
23
. We consider response at three, six and twelve months after treatment 





The study was conducted in accordance with the 2008 Declaration of Helsinki and in the spirit of the 
1996 International Conference on Harmonisation in Good Clinical Practice. Ethical approval for this 
study was granted by The South East London REC 2 Ethics Committee (11/H0802/7).  Written 
informed consent was obtained from all subjects prior to enrolment. 
All participants are adults (>16 years) enrolled in the Biomarkers of Systemic Treatment 
Outcomes in Psoriasis study (BSTOP; https://www.kcl.ac.uk/lsm/research/divisions/gmm/
departments/dermatology/Research/stru/groups/bstop/index.aspx) and the British Association of 
Dermatologists Biologic and Immunomodulators Register (BADBIR; www.badbir.org). BSTOP is a 
prospective observational study across 60 UK dermatology centres that includes biological sample 
collection. It aims to establish clinically relevant markers of outcomes to systemic therapies in severe 
psoriasis (study protocol: https://www.kcl.ac.uk/ContensisManagedLinks/BSTOP-Protocol-Version-
5.pdf). BADBIR is a pharmacovigilance register that has recruited >16,000 psoriasis patients 
undertaking systemic conventional or biological therapy in the UK and Ireland. It seeks to assess the 
long-term safety of biologic treatments for psoriasis. Enrolment criteria for the biologic arm for both 
BSTOP and BADBIR include diagnosis and prescription of systemic therapy by a dermatologist. 
 
Clinical data 
Detailed clinical data are recorded by BSTOP and BADBIR at registration and at regular follow-up 















area and severity index (PASI) assessments of disease severity, treatment details, adverse events and 
comorbidities. Clinical data were extracted on 1
st
 July 2017. Data derived from BSTOP and BADBIR 
were merged, and processes were established to identify and resolve inconsistencies between data 
sources in collaboration with local clinical teams. For a minority of patients appropriate assumptions 
were employed to demarcate periods of treatment: treatment was considered ongoing where 
treatment episodes for the same biologic were separated by less than 90 days
24
; missing treatment 
end dates were imputed based on the start date of subsequent biologic treatment, allowing a 28 day 
washout period; and patients were considered to be continuing treatment at the data extract date 
where no end date was recorded. Age of psoriasis onset was inferred from the recorded year of 
onset. Patients were assumed to be positive for psoriatic arthritis (PsA) if reported at BADBIR 
registration or at any subsequent follow-up prior to the data extract date (92.8% diagnosed by a 
rheumatologist). 
 
Genotype data and HLA imputation 
DNA was isolated from blood using standard methods. Genotyping was performed using Illumina 
HumanOmniExpressExome-8 v1.2 and v1.3 BeadChips followed by quality control using standard 
tools
25-28
 and procedures as detailed in Supplementary Methods. The final dataset was limited to 
patients of European ancestry. Classical HLA alleles were imputed using SNP2HLA (v1.0.3), based on 
the T1DGC reference panel
29
. We excluded poorly imputed alleles (R
2
 < 0.9) and alleles with 
frequency <0.01, giving a total of 142 distinct 2- and 4-digit imputed alleles. 
 
Data integration and definition of response 
Patients with both genotype data and response data for the first course of treatment for either drug 
(adalimumab or ustekinumab) were considered for analysis. Patients were required to have a 
baseline PASI score (up to six months prior to treatment initiation) of >10, and a response PASI score 
recorded sufficiently close to at least one response time-point (±30 days from 3m; ±60 days from 6m 
and 12m time-points) while still on treatment. 101 patients with eligible records for both treatments 
were randomly assigned to the adalimumab or ustekinumab groups (50/51 patients respectively), 
with their other record being excluded from the analysis. This did not materially impact results 
(Table E18). The final integrated dataset included observations for 1,326 patients. 
For each patient observed at each response time-point, PASI90 response was achieved if the 
response PASI score represented a reduction of 90% or more relative to baseline PASI. Secondary 

















All statistical models were implemented in R
27, 30
. Associations between patient characteristics and 
drug type were established via regression modelling (linear regression for continuous characteristics; 
logistic regression for binary characteristics) with drug type (adalimumab vs ustekinumab) as the 
sole explanatory variable. Associations with HLA-C*06:02 were established using regression models 




At each response time-point, multivariable logistic regression modelling was employed with 
binary PASI90 response as the dependent variable (PASI75/PASI100 for secondary outcomes) and 
baseline PASI as a covariate. Drug type and HLA-C*06:02 dosage were included as main effects and 
as a drug × HLA-C*06:02 interaction term: a statistically significant non-zero interaction effect would 
implicate HLA-C*06:02 as a predictive biomarker. To generate the full multivariable model 
accounting for potential clinical confounders, main effect and interaction covariate terms were 
added based on correlations with HLA-C*06:02 or drug (Table 1). For variables significantly 
correlated with HLA-C*06:02 (age of onset, baseline PASI, disease duration and PsA), an interaction 
term with drug was included, and for variables significantly correlated with drug (PsA and biologic 
naive status) an interaction term with HLA-C*06:02 was included. The full model is described in 
Supplementary Methods. Missing observations for age of onset or PsA status covariates were 
replaced by mean-imputed values derived from HLA-C*06:02-positive and negative subgroups. 
Models of response were fitted within HLA-C*06:02- and PsA-defined subgroups; these included a 
term for drug type and a covariate term for baseline PASI only. 
To confirm that our full multivariable model adequately controlled for potential confounding 
via covariates influencing treatment selection, we repeated the regression analysis with inverse 
probability of treatment weighting using the propensity score
33
. Weighted regression was 
implemented using the ‘survey’ package in R
34
. See Supplementary Methods for full details.  
HLA-wide analysis was performed for 142 2- and 4-digit alleles having a frequency >1% in 
our full genotyped cohort of 3,320 patients. The full interaction model was fitted based on imputed 
dosage for each allele in turn, substituting the HLA-C*06:02 main effect and interaction terms. 
Conditional analysis was performed by including main effect and interaction terms for both 
HLA-C*06:02 and the alternative alleles. 
ERAP1 interaction analysis was based on the genotyped variant rs27524
15
. Psoriasis 
susceptibility epistasis was confirmed via case-only association testing in the full cohort of 3,320 
patients, treating HLA-C*06:02 status as a binary trait. To test for interaction with respect to 















main effect term for rs27524 genotype, first-order interaction terms rs27524 genotype × 
HLA-C*06:02 dosage and rs27524 genotype × drug, and second-order interaction term rs27524 
genotype × HLA-C*06:02 dosage × drug. Power analysis for the ERAP1 interaction test conducted in 
the HLA-C*06:02-negative subgroup was conducted using the method of Demidenko 
(https://www.dartmouth.edu/~eugened/power-samplesize.php)
35
. Assumptions of the method 
required rs27524 genotype be collapsed to a binary variable (for the purposes of power estimation 




Results section 1: A prospective observational data resource facilitating predictive genetic 
biomarker identification in psoriasis 
To assess the ability of HLA-C*06:02 to predict different rates of response to adalimumab and 
ustekinumab we considered 3,320 patients enrolled in the Biomarkers of Systemic Treatment 
Outcomes in Psoriasis (BSTOP) study and the British Association of Dermatologists Biologic and 
Immunomodulators Register (BADBIR) for whom genotype data were available (Methods). 53.4% of 
these patients were HLA-C*06:02 positive (carrying at least one copy of the allele), with 46.6% being 
HLA-C*06:02 negative. After applying eligibility criteria to ensure that valid baseline and response 
PASI scores were available, 1,326 participants were included in the final analyses (Figure 1). 
Participant baseline characteristics are summarised in Table 1. Since our investigation 
concerns the relationship between HLA-C*06:02 and drug used for treatment (adalimumab or 
ustekinumab), we sought to identify clinical variables correlated with either of these. We found a 
strong association between age of psoriasis onset and imputed HLA-C*06:02 dosage (i.e. a 





. HLA-C*06:02 was also associated with baseline PASI score and with 
duration of disease at treatment initiation (P = 0.031 and P = 3.61×10
-9
 respectively). The 
relationship between HLA-C*06:02 and the presence of PsA is complex
36
, but we observed a 
statistically significant correlation (P = 8.44×10
-3
) that persisted even after controlling for age of 
psoriasis onset (Padjusted = 3.98×10
-3
). PsA was also significantly associated with drug type (P = 0.017), 
likely reflecting a tendency towards prescription of anti-TNF therapy for patients with PsA due to its 
beneficial effect on joint disease
37
. We observed an unexpected association between HLA-C*06:02 
and methotrexate co-therapy at the start of biologic treatment (P = 0.027). Co-therapy is common in 
patients with PsA, and indeed the association disappears when controlling for PsA status 















strongly correlated with drug type (P = 2.12×10
-32
), reflecting the frequent use of adalimumab as a 
first-line biologic in this patient population
37
; it was not associated with HLA-C*06:02 genotype 
(P = 0.411). 
The observed rate of PASI90 response to adalimumab (41.9% at 3m; 49.5% at 6m) was 
consistent with that reported in clinical trials (45% at 16 weeks)
9
, while the observed ustekinumab 
rate (28.2% at 3m) was lower than the corresponding trial rate (39% at 12 weeks)
10
 (Table 2). 
Observed response rates by HLA-C*06:02 status and for PASI75 and PASI100 outcomes are given in 
Table E1. 
 
Results section 2: HLA-C*06:02 is an effective biomarker that could inform treatment selection 
We investigated the extent to which HLA-C*06:02 genotype is predictive of different rates of PASI90 
response for adalimumab compared to ustekinumab. Formally, for each time-point (3m, 6m and 
12m after treatment initiation) we fitted a logistic regression model for PASI90 response that 
included an interaction term between imputed HLA-C*06:02 dosage and drug type (adalimumab and 
ustekinumab) (Methods). These are effectively gene-environment interaction models (GxE), where a 
statistically significant non-zero interaction term indicates that HLA-C*06:02 can stratify response. 
A significant interaction term was observed in basic models that considered only HLA-
C*06:02 dosage and drug (Table E2). However, we took two further steps to ensure that these 
findings were not primarily driven by the effect of confounding clinical variables reported in Table 1. 
First, we developed multivariable regression models to test for drug × HLA-C*06:02 interaction that 
included appropriate main effect and interaction covariate terms (Methods). We observed 
statistically significant non-zero effects at all time-points for the drug × HLA-C*06:02 interaction 
term (Table 2). The strongest evidence for interaction was observed at the 6m time-point where 
sample numbers were largest (P = 3.76×10
-5
). A significant interaction effect was also observed for 
the secondary outcome of PASI75, and for all but the earliest time-point (3m) for PASI100 (Table E3). 
Second, we employed a propensity-score-weighted approach to adjust for potential 
confounding via covariates influencing treatment selection (full details in Supplementary Methods). 
We observed that all covariates were well balanced between adalimumab and ustekinumab groups 
after weighting (Table E4, Figure E1). The drug × HLA-C*06:02 interaction terms remained significant 
at all time-points in the weighted models, at very similar levels of significance to the full unweighted 
multivariable models (Table E5). As such we are confident that our full unweighted model 
















To elucidate the observed drug × HLA-C*06:02 interaction effect, we examined the effect 
that drug type exerts on probability of response within two subgroups of patients: HLA-C*06:02 
negative (zero copies of the allele) and HLA-C*06:02 positive (one or two copies; pooled due to the 
small number of patients that carry two copies). At all time-points, drug type was associated with 
PASI90 response among HLA-C*06:02 negative patients (better response to adalimumab; 
OR6m = 2.95, P6m = 5.85×10
-7
), but not among HLA-C*06:02 positive patients (Table 3, Figure 2A). This 
trend was also observed for the secondary PASI75 and PASI100 outcomes (Table E6, Figure E2). 
We performed separate multivariate regression analyses within adalimumab and 
ustekinumab groups, including covariate main effects only. These confirmed that while there is some 
effect size heterogeneity across time-points, HLA-C*06:02 is associated with response to both drugs 
individually. It is associated with better response to ustekinumab (PASI90 OR6m = 1.72, P6m = 0.018), 
consistent with previous reports
19-21
, and poorer response to adalimumab (PASI90 OR6m = 0.54, 
P6m = 1.67×10
-4
), which has not previously been established (Table E7, Figure E3). The opposite 
effect directions give rise to the observed drug × HLA-C*06:02 interaction. 
Nominally significant interactions are observed between PsA and drug at 12m, and between 
PsA and HLA-C*06:02 genotype at 3m (Table 2). We tested the effect of drug type on PASI90 
response within patient subgroups characterised by both HLA-C*06:02 status (positive/negative) and 
PsA status (presence/absence) (Table 3, Figure 2B). In HLA-C*06:02 negative patients, the effect of 
drug type on likelihood of PASI90 response was stronger at all time-points among patients with PsA 
(OR6m = 5.98, P6m = 6.89×10
-5
) than among patients without PsA (OR6m = 2.32, P6m = 1.41×10
-3
; not 
significant at 12m). Conversely, among HLA-C*06:02 positive patients the only significant difference 
in PASI90 response by drug comprised a weak association in the HLA-C*06:02 positive and PsA 
negative group at 12m, where adalimumab demonstrated poorer rates of response than 
ustekinumab (OR = 0.56, P = 0.018). The same trends held true in general for PASI75 and PASI100 
outcomes (Table E8). 
We note that biologic naive status has a stronger direct effect than drug type on the 
likelihood of achieving PASI90 response (Table E9). However, Table 2 shows clearly that in the full 
model HLA-C*06:02 has a significant GxE interaction with drug and not with biologic naive status. 
The different relative response rates to adalimumab and ustekinumab among HLA-C*06:02 positive 
and negative patients are therefore likely to be drug-specific and not explained by these two groups 
having different propensities to respond to biologic therapy when accounting for previous biologic 
exposure. Fitting the multivariable GxE models in biologic naive patients only (925 of 1,326 patients) 
confirmed a drug × HLA-C*06:02 interaction effect of similar magnitude to the main analysis (Tables 















ustekinumab at 12m in HLA-C*06:02 positive and PsA negative patients is much more striking in this 
biologic naive group (OR12m = 0.31, P12m = 3.42×10
-4
) (Table E11, Figure E4b). When considering 
biologic experienced patients only the drug × HLA-C*06:02 interaction effect does not achieve 
statistical significance at any time-point, potentially due to much smaller sample sizes (Tables E10 
and E11). Nevertheless, the same general trend is observed: the subgroup with the biggest 
difference in response rates are HLA-C*06:02 negative and PsA positive patients (better response to 
adalimumab), while HLA-C*06:02 positive and PsA negative patients see marginally better response 
to ustekinumab (Figure E5). 
Finally, our data show a trend suggesting that ustekinumab may be more effective than 
adalimumab at inducing PASI90 response among the subgroup of HLA-C*06:02 positive patients 
homozygous for the allele, regardless of PsA status (Figure E6). This suggests an additive genetic 
effect of HLA-C*06:02 on differential treatment response. Larger sample sizes are required to fully 
investigate the significance of this observation and its implications for clinical practice. 
 
Results section 3: Among all HLA alleles, HLA-C*06:02 displays the strongest evidence for being a 
predictive biomarker 
While HLA-C*06:02 has been established as the allele most highly associated with psoriasis 
susceptibility, it is possible that distinct HLA-C alleles or alleles of other class I or class II MHC genes 
might elicit an enhanced anti-drug immune response to one of the drugs and consequently better 
predict differential treatment response. We therefore repeated our analysis for all 142 2- and 4-digit 
HLA alleles that were imputed with high confidence (Methods), using the same full GxE model as for 
HLA-C*06:02 (Table E12). We confirmed that HLA-C*06:02 displays the strongest evidence for a drug 
× HLA allele interaction for 6m PASI90 response, demonstrating statistical significance at a 
Bonferroni-corrected p-value threshold of 1.17×10
-4
 (based on 426 tests: 142 alleles × 3 time-points) 
(Figure 3). Results at other time-points were not inconsistent with this, no HLA alleles achieving 
significance at the Bonferroni-corrected threshold (Table E12). A similar pattern was also observed 
for the secondary PASI75 and PASI100 outcomes (Table E12, Figure E7). These findings suggest that 
HLA-C*06:02 is likely to be the primary effect allele contributing to biologic response, but due to the 
extensive linkage disequilibrium across this region larger samples will be necessary to fully 
investigate the role of other HLA alleles. 
To identify potential independent secondary predictive biomarkers in the HLA region, we 
also report the most associated 2- and 4-digit HLA alleles after conditioning on HLA-C*06:02 (main 
and interaction terms) (Table E13). No alleles achieved p-values below the Bonferroni-corrected 
significance threshold of 1.17×10
-4















for HLA-B alleles; we found little evidence to support independent secondary predictive biomarkers 
at MHC class II genes. Note that full results for all HLA alleles are provided in Table E14. 
 
Results section 4: No evidence observed for an interaction with ERAP1 genotype 
Variants such as rs27524 in ERAP1 exhibit an epistatic effect on psoriasis susceptibility through 
interaction with HLA-C*06:02, with each copy of the risk allele amplifying the increase in disease risk 
that positive HLA-C*06:02 status confers
15
. Case-only analysis in our full cohort of 3,320 patients 




We sought to establish whether a similar effect is observed for differential response to 
adalimumab versus ustekinumab. We found no evidence for epistasis based on two complementary 
approaches: a full model including the second-order interaction term rs27524 genotype × HLA-
C*06:02 dosage × drug (effectively a gene-gene-environment (GxGxE) model; Table E15), and a 
simple GxE model within the subgroup of 622 HLA-C*06:02 negative patients (in which differential 
response by drug was previously observed) that included the interaction term rs27524 genotype × 
drug (Table E16). When removing the (non-significant) second-order interaction term from the 
GxGxE model, significant p-values are observed for HLA-C*06:02 dosage × drug, as expected, but for 
neither interaction term involving the ERAP1 variant (Table E17). 
We estimate that our sample sizes provide 80% power to detect interactions between 
ERAP1 and drug in the HLA-C*06:02 negative subgroup when interaction effect sizes (beta regression 
parameters) are larger than 1.62, 1.28 and 1.37 at 3m, 6m and 12m respectively. Since such effects 
were not observed we find no evidence to suggest that an interaction between ERAP1 and HLA-
C*06:02 could provide a more effective predictive biomarker than HLA-C*06:02 alone. A similar 
conclusion holds when considering the secondary outcomes, PASI75 and PASI100 (Tables E15, E16 
and E17).  
 
Discussion 
This study constitutes the largest investigation to date into the pharmacogenetics of biologic 
response in psoriasis, and the first to utilise jointly generated clinical and genetic data on different 
drugs to identify a predictive biomarker with potential clinical utility. We report that the 
HLA-C*06:02 allele effectively stratifies psoriasis patients into groups with different profiles of 
response to the two most frequently prescribed biologics, adalimumab and ustekinumab. 
While the scale of our clinical data resource makes it highly representative of the UK 
psoriasis population
38, 39















lack a structured series of PASI observations at fixed time-points. This limits more formal longitudinal 
analyses. Similarly, baseline PASI scores are defined pragmatically. They can precede treatment by 
up to six months and may have been recorded during alternative treatment, although we took steps 
to minimise any resulting bias (Methods). Adverse drug reactions, not investigated here, represent 
another important consideration when selecting treatment. Independent replication will be 




Our results demonstrate that HLA-C*06:02 negative psoriasis patients are significantly more 
likely to respond to adalimumab than to ustekinumab, but that there is no significant benefit to 
adalimumab over ustekinumab in HLA-C*06:02 positive patients. 
We also find that the effect of HLA-C*06:02 is modulated by the presence or absence of 
comorbid PsA, with adalimumab conferring the greatest benefit over ustekinumab in patients that 
are HLA-C*06:02 negative and PsA positive (31.9% of all patients with PsA status available). 
Interestingly, these findings demonstrate the effectiveness of adalimumab at treating psoriatic skin 
disease only. Further investigation of the ability of HLA genes to predict combined skin and joint 
response for PsA positive psoriasis patients is therefore warranted – ideally via longitudinal studies 
that collect separate validated objective measurements for both skin and joint involvement. 
Through HLA imputation we estimated that 46.6% of severe psoriasis patients are 
HLA-C*06:02 negative. While treatment selection should always be considered on a case-by-case 
basis
11
, our results suggest that a default strategy of ascertaining HLA-C*06:02 status and 
administering adalimumab as first-line biologic to HLA-C*06:02 negative patients may be an effective 
approach. Of the 53.4% of patients that are HLA-C*06:02 positive, Table 1 suggests that more than 
three-quarters will not have active PsA. This group may benefit from ustekinumab as a default first-
line treatment over the longer term (Figure E4), particularly in light of its longer dosing intervals and 
better persistence relative to adalimumab
40
. Our findings are not conclusive for patients that are 
HLA-C*06:02 positive and PsA positive. Since adalimumab is already the recommended first-line 
biologic in the UK when PsA is present
11
, our recommendations primarily impact the 71.8% of 
patients without active PsA (Table 1). HLA-C*06:02-informed treatment selection could therefore 
offer improved likelihood of PASI90 response through the first 12 months of treatment for 35.9% of 
all severe psoriasis patients, compared to random assignment to adalimumab or ustekinumab. We 
acknowledge that random assignment does not reflect current clinical practice in this patient 
population
37
. However, current UK guidelines do not favour either adalimumab or ustekinumab in 
the absence of PsA
11















that our recommendations will have health economic implications as adalimumab biosimilars 
emerge. 
The results presented here support the notion that HLA-C*06:02 positive and HLA-C*06:02 
negative plaque psoriasis represent biologically distinct pathologies, or endotypes. Differences in 
presentation have long been recognised
16
. However, we suggest that with the implications for 
clinical decision-making raised by our findings, HLA-C*06:02 status represents a more relevant 




It is widely accepted that HLA-C*06:02 is the genetic allele that makes by far the largest 
individual contribution to the risk of developing psoriasis
42-44
. Intriguingly, our HLA-wide analysis 
suggests that this allele is also mechanistically relevant to biologic response among patients 
(Figure 3, Table E12). As such, it is unlikely that HLA-C*06:02 should generalise as a predictive 
biomarker for biologic response in other immune-mediated inflammatory diseases. Conversely, 
these findings may shed important light on the complex pathogenic mechanisms underlying 
psoriasis. The difference in response to the two drugs among HLA-C*06:02 negative patients 
suggests that aberrant signalling of immune pathways downstream of TNFα, adalimumab’s target 
molecule, may play a more prominent role in the development and maintenance of psoriatic lesions 
for these individuals than for HLA-C*06:02 positive patients. 
Further investigation of the genetic, transcriptomic and immunological differences between 
HLA-C*06:02 positive and negative patients could offer vital insights into the pathophysiology of 
psoriasis and mechanisms of treatment response. Much larger sample sizes will be required to 
provide sufficient statistical power to accurately quantify the effect of HLA-C*06:02 and refine the 
contributions of other HLA alleles. More generally, genome-wide analyses have the potential to 
uncover genetic contributions to treatment response beyond the HLA region. The genotype data 
utilised in this study will contribute to such efforts, and results are eagerly anticipated. With respect 
to clinical application, the potential impact of our findings on patient outcomes is substantial, but it 
will be important to validate our findings more formally in an appropriately structured prospective 
clinical trial setting. The design of such a trial should also formally account for PsA status and the 
clinical factors most likely to confound observational studies, such as previous biologic exposure. 
In summary, we show that HLA-C*06:02 status is a predictive biomarker that influences 
response to adalimumab and ustekinumab. Ascertainment of HLA-C*06:02 genotype is 
straightforward, and our results could have substantial clinical relevance when selecting between 
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Table 1 –Summary statistics for baseline characteristics and potential confounding clinical variables 
Negative HLA-C*06:02 status: no copies of the allele; positive status: one or two copies of the allele; PASI: Psoriasis Area and Severity Index. P-values indicated are derived 
from regression modelling (linear/logistic regression for continuous/binary characteristics respectively); in particular, the HLA-C*06:02 p-values are based on imputed HLA-




By drug By HLA-C*06:02 status 
  Adalimumab Ustekinumab P Negative Positive P 




Baseline PASI score (mean ± SD) 16.7 ± 6.4 16.8 ± 6.5 16.6 ± 6.3 0.551 17.1 ± 6.6 16.4 ± 6.3 0.031 
Age of disease onset (mean ± SD) 
a
 21.8 ± 12.6 21.4 ± 12.2 22.4 ± 13.2 0.173 25.6 ± 12.8 18.5 ± 11.4 9.38×10
-22
 




23.3 ± 12.6 22.8 ± 12.1 24.0 ± 13.4 0.121 20.7 ± 11.5 25.5 ± 13.1 3.61×10
-9
 
Psoriatic arthritis (%) 
b





Biologic naïve (%) 69.8 81.5 49.5 2.12×10
-32
 69.3 70.2 0.411 




 Based on 1,177 patients (89%) with age of disease onset recorded; 
b
 Based on 1,275 patients (96%) with PsA status recorded; 
c
 P = 3.98×10
-3
 when controlling for age of 
onset; 
d















Table 2 – HLA-C*06:02 is a predictive biomarker of PASI90 response to adalimumab or ustekinumab 
after accounting for potential confounding variables 
Results are presented for the model interaction terms only. Results for other model terms are not shown; in 
particular main effect terms are not unambiguously interpretable in the presence of an interaction term. 
Table 3 further elucidates the effects of HLA-C*06:02 and PsA status. 
 
PASI90 response 
  3 months 6 months 12 months 
n adalimumab 401 586 514 
      adalimumab responders 168 (41.9%) 290 (49.5%) 257 (50.0%) 
n ustekinumab 245 325 298 
      ustekinumab responders 69 (28.2%) 130 (40.0%) 139 (46.6%) 
n total 646 911 812 
Drug × BL PASI interaction 
   
      Effect size (beta) -0.045 0.038 -0.010 
      95% CI (-0.109, 0.018) (-0.008, 0.084) (-0.062, 0.043) 
      P-value 0.162 0.108 0.724 
Drug × Age of Onset interaction 
   
      Effect size (beta) 0.009 -0.003 -0.001 
      95% CI (-0.026, 0.044) (-0.031, 0.026) (-0.030, 0.028) 
      P-value 0.605 0.861 0.932 
Drug × Disease Duration interaction 
   
      Effect size (beta) 0.024 -0.014 0.001 
      95% CI (-0.009, 0.058) (-0.043, 0.014) (-0.028, 0.031) 
      P-value 0.156 0.329 0.928 
Drug × PsA interaction 
   
      Effect size (beta) -0.102 0.491 0.934 
      95% CI (-1.000, 0.795) (-0.209, 1.191) (0.215, 1.654) 
      P-value 0.823 0.169 0.011 
HLA-C*06:02 × PsA interaction 
   
      Effect size (beta) -0.926 -0.175 0.327 
      95% CI (-1.649, -0.203) (-0.725, 0.374) (-0.261, 0.916) 
      P-value 0.012 0.531 0.276 
HLA-C*06:02 × Biologic Naive interaction 
   
      Effect size (beta) -0.326 0.101 0.152 
      95% CI (-1.079, 0.427) (-0.495, 0.696) (-0.464, 0.768) 
      P-value 0.396 0.741 0.629 
Drug × HLA-C*06:02 interaction 
   
      Effect size (beta) -0.901 -1.198 -0.921 
      95% CI (-1.641, -0.161) (-1.768, -0.628) (-1.503, -0.340) 




















Table 3 – Association of drug type with PASI90 response by HLA-C*06:02 status and presence of concomitant psoriatic arthritis 
PsA: psoriatic arthritis (concomitant with psoriasis – see Methods for PsA definition; note that PsA subgroup numbers sum to less than “All” numbers, due to a minority of 
patients without PsA status recorded). 
 
 
All Subgroup without PsA Subgroup with PsA 
 
3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
HLA-C*06:02 Negative          
    n adalimumab 195 265 243 124 159 160 66 100 79 
        adalimumab responders 80 (41.0%) 154 (58.1%) 133 (54.7%) 47 (37.9%) 87 (54.7%) 86 (53.8%) 33 (50.0%) 62 (62.0%) 44 (55.7%) 
    n ustekinumab 113 153 137 83 109 93 26 38 39 
        ustekinumab responders 20 (17.7%) 50 (32.7%) 55 (40.1%) 16 (19.3%) 39 (35.8%) 43 (46.2%) 3 (11.5%) 8 (21.1%) 9 (23.1%) 
    n total 308 418 380 207 268 253 92 138 118 
  Drug: adalimumab vs 
ustekinumab 
         
        Odds ratio 3.271 2.950 1.860 2.586 2.316 1.430 7.423 5.977 4.076 
        95% CI (1.846, 5.795) (1.930, 4.510) (1.207, 2.867) (1.330, 5.027) (1.383, 3.878) (0.845, 2.420) (1.984, 27.769) (2.478, 14.417) (1.707, 9.733) 


















         
    n adalimumab 206 321 271 150 231 198 47 82 65 
        adalimumab responders 88 (42.7%) 136 (42.4%) 124 (45.8%) 69 (46.0%) 99 (42.9%) 84 (42.4%) 17 (36.2%) 33 (40.2%) 36 (55.4%) 
    n ustekinumab 132 172 161 91 128 115 35 37 41 
        ustekinumab responders 49 (37.1%) 80 (46.5%) 84 (52.2%) 35 (38.5%) 60 (46.9%) 63 (54.8%) 12 (34.3%) 15 (40.5%) 19 (46.3%) 
    n total 338 493 432 241 359 313 82 119 106 
  Drug: adalimumab vs 
ustekinumab          
        Odds ratio 1.266 0.841 0.738 1.366 0.846 0.565 1.057 0.978 1.461 
        95% CI (0.806, 1.987) (0.579, 1.221) (0.495, 1.102) (0.801, 2.329) (0.548, 1.307) (0.351, 0.907) (0.417, 2.680) (0.442, 2.166) (0.657, 3.251) 

















Figure 1 – Flow diagram of study eligibility 
BADBIR: British Association of Dermatologists Biologic and Immunomodulators Register; BSTOP: Biomarkers of 
Systemic Treatment Outcomes in Psoriasis; PASI: Psoriasis Area and Severity Index. 
 
 
Figure 2 – Differential effect of adalimumab and ustekinumab depends on HLA-C*06:02 status and 
can be further discriminated by presence of concomitant psoriatic arthritis 
Proportion of patients achieving PASI90 response: (A) by HLA-C*06:02 status (negative: no copies of the allele; 
positive: one or two copies of the allele); (B) by HLA-C*06:02 status and PsA status. Displayed 95% confidence 
intervals are derived from the Bayesian credible interval using the Jeffreys prior. PsA: psoriatic arthritis 
(concomitant with psoriasis – see Methods for PsA definition). 
 
 
Figure 3 – GxE interaction p-values for PASI90 response across common 2- and 4-digit HLA alleles 
Top panel: GxE interaction p-value by HLA allele; bottom panel: GxE interaction p-value by HLA allele after 
conditioning on HLA-C*06:02 main effect and interaction terms; y-axis: -log10(p-value); dark red dashed line: 
Bonferroni-corrected significance threshold of 1.17×10
-4
; grey dashed line: nominal significance threshold of 
0.05. Time-points are represented by different shaped points. Note that the x-axis represents HLA allele as a 
categorical variable ordered lexicographically, and does not represent scaled chromosome position. In each 
panel the most significantly associated allele at each time-point is labelled and highlighted by a grey circle. For 
ease of identification HLA-C*06:02 p-values for the three time-points are joined by a dotted green line; there 
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Figure E1 – Standardised mean differences in covariates between adalimumab and ustekinumab 
treatment groups before and after inverse probability of treatment weighting using the propensity 
score 
Covariates ordered by size of SMD before inverse probability of treatment weighting adjustment. Blue line 
indicates accepted threshold of 0.1 below which covariates are effectively balanced between treatment 
groups. SMD: standardised mean difference; PsA: psoriatic arthritis; mtx: methotrexate; PC: (ancestry) 
principal component; AoO_est: estimated age of disease onset (including imputed values; see Methods); 
PASI_BL: baseline PASI. 
 
 
Figure E2 - Differential effect of adalimumab and ustekinumab depends on HLA-C*06:02 status 
Proportion of patients achieving PASI75 or PASI100 response, by HLA-C*06:02 status (negative: no copies of 
the allele; positive: one or two copies of the allele). Displayed 95% confidence intervals are derived from the 
Bayesian credible interval using the Jeffreys prior. 
 
Figure E3 – Size of HLA-C*06:02 main effect on PASI75, PASI90 and PASI100 response by drug 
OR: odds ratio; CI: confidence interval. 
 
Figure E4 - Differential effect of adalimumab and ustekinumab by HLA-C*06:02 status and psoriatic 
arthritis status, in biologic naive patients only 
Proportion of biologic naive patients achieving PASI90 response: (A) by HLA-C*06:02 status (negative: no 
copies of the allele; positive: one or two copies of the allele); (B) by HLA-C*06:02 status and PsA status. 
Displayed 95% confidence intervals are derived from the Bayesian credible interval using the Jeffreys prior. 
PsA: psoriatic arthritis (concomitant with psoriasis – see Methods for PsA definition). 
 
Figure E5 - Differential effect of adalimumab and ustekinumab by HLA-C*06:02 status and psoriatic 
arthritis status, in biologic experienced patients only 
Proportion of biologic experienced patients achieving PASI90 response: (A) by HLA-C*06:02 status (negative: 
no copies of the allele; positive: one or two copies of the allele); (B) by HLA-C*06:02 status and PsA status. 
Displayed 95% confidence intervals are derived from the Bayesian credible interval using the Jeffreys prior. 
PsA: psoriatic arthritis (concomitant with psoriasis – see Methods for PsA definition). 
 
Figure E6 – Cohort analysis suggests that the differential effect of adalimumab and ustekinumab 
by HLA-C*06:02 status and psoriatic arthritis status extends to genotype 
Proportion of patients achieving PASI90 response: (A) by HLA-C*06:02 genotype; (B) by HLA-C*06:02 genotype 
and PsA status. Displayed 95% confidence intervals are derived from the Bayesian credible interval using the 















Figure E7 - GxE interaction p-values for PASI75 and PASI100 response across common 2- and 4-
digit HLA alleles  
(a) PASI75 response; (b) PASI100 response. Top panel: GxE interaction p-value by HLA allele; bottom panel: 
GxE interaction p-value by HLA allele after conditioning on HLA-C*06:02 main effect and interaction terms; y-
axis: -log10(p-value); dark red dashed line: Bonferroni-corrected significance threshold of 1.17×10
-4
; grey 
dashed line: nominal significance threshold of 0.05. Time-points are represented by different shaped points. 
Note that the x-axis represents HLA allele as a categorical variable ordered lexicographically, and does not 
represent scaled chromosome position. In each panel the most significantly associated allele at each time-
point is labelled and highlighted by a grey circle. For ease of identification HLA-C*06:02 p-values for the three 



































      
    n 206 195 401 132 113 245 
    PASI75 response 147 (71.4%) 132 (67.7%) 279 (69.6%) 90 (68.2%) 55 (48.7%) 145 (59.2%) 
    PASI90 response 88 (42.7%) 80 (41.0%) 168 (41.9%) 49 (37.1%) 20 (17.7%) 69 (28.2%) 
    PASI100 response 45 (21.8%) 44 (22.6%) 89 (22.2%) 23 (17.4%) 13 (11.5%) 36 (14.7%) 
6m time-point 
      
    n 321 265 586 172 153 325 
    PASI75 response 235 (73.2%) 207 (78.1%) 442 (75.4%) 124 (72.1%) 89 (58.2%) 213 (65.5%) 
    PASI90 response 136 (42.4%) 154 (58.1%) 290 (49.5%) 80 (46.5%) 50 (32.7%) 130 (40.0%) 
    PASI100 response 78 (24.3%) 96 (36.2%) 174 (29.7%) 43 (25.0%) 21 (13.7%) 64 (19.7%) 
12m time-point 
      
    n 271 243 514 161 137 298 
    PASI75 response 208 (76.8%) 196 (80.7%) 404 (78.6%) 119 (73.9%) 92 (67.2%) 211 (70.8%) 
    PASI90 response 124 (45.8%) 133 (54.7%) 257 (50.0%) 84 (52.2%) 55 (40.1%) 139 (46.6%) 

















Table E2 – Significant interaction of drug and HLA-C*06:02 genotype in achievement of PASI90 
response (uncorrected model) 
Based on logistic regression model of PASI90 response that includes baseline PASI and five ancestry 
principal components as the only covariates (no adjustment for clinical confounders). Results are 
presented only for the drug × HLA-C*06:02 interaction term in the GxE model. Results for other 
model terms are not shown; in particular the terms for HLA-C*06:02 and drug main effects are not 
unambiguously interpretable (due to the presence of an interaction term between the two, the 




  3 months 6 months 12 months 
n adalimumab 401 586 514 
n ustekinumab 245 325 298 
      n total 646 911 812 
Drug × HLA-C*06:02 interaction 
   
      Effect size (beta) -0.894 -1.221 -0.859 
      95% CI (-1.535, -0.253) (-1.739, -0.702) (-1.382, -0.337) 




























PASI75 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 401 586 514 401 586 514 
n ustekinumab 245 325 298 245 325 298 
      n total 646 911 812 646 911 812 
Drug × BL PASI interaction 
      
      Effect size (beta) -0.032 0.033 -0.061 -0.021 0.051 0.025 
      95% CI (-0.101, 0.037) (-0.018, 0.084) (-0.125, 0.004) (-0.095, 0.053) (-0.003, 0.105) (-0.029, 0.079) 
      P-value 0.365 0.208 0.065 0.583 0.063 0.364 
Drug × Age of Onset interaction 
      
      Effect size (beta) 0.008 -0.001 -0.003 0.019 0.012 -0.015 
      95% CI (-0.026, 0.043) (-0.032, 0.031) (-0.038, 0.033) (-0.024, 0.062) (-0.022, 0.046) (-0.046, 0.016) 
      P-value 0.634 0.969 0.886 0.390 0.488 0.351 
Drug × Disease Duration interaction 
      
      Effect size (beta) 0.028 -0.003 -0.008 0.030 0.011 -0.007 
      95% CI (-0.006, 0.061) (-0.034, 0.028) (-0.041, 0.025) (-0.010, 0.071) (-0.023, 0.046) (-0.040, 0.025) 
      P-value 0.105 0.851 0.639 0.143 0.519 0.662 
Drug × PsA interaction 
      
      Effect size (beta) -0.443 0.836 0.924 -0.725 0.234 0.854 
      95% CI (-1.267, 0.381) (0.114, 1.557) (0.139, 1.709) (-1.777, 0.327) (-0.611, 1.079) (0.042, 1.666) 
      P-value 0.292 0.023 0.021 0.177 0.587 0.039 
HLA-C*06:02 × PsA interaction 
      
      Effect size (beta) -0.782 0.022 0.248 -0.743 -0.262 0.107 
      95% CI (-1.488, -0.077) (-0.566, 0.611) (-0.424, 0.920) (-1.588, 0.103) (-0.885, 0.362) (-0.530, 0.744) 















HLA-C*06:02 × Biologic Naive interaction 
      
      Effect size (beta) -0.184 0.387 0.412 -0.372 -0.048 -0.029 
      95% CI (-0.909, 0.541) (-0.229, 1.003) (-0.260, 1.083) (-1.264, 0.519) (-0.788, 0.692) (-0.718, 0.661) 
      P-value 0.619 0.218 0.230 0.413 0.899 0.935 
Drug × HLA-C*06:02 interaction 
      
      Effect size (beta) -0.832 -1.026 -0.854 -0.504 -1.199 -0.724 
      95% CI (-1.568, -0.097) (-1.648, -0.405) (-1.521, -0.187) (-1.377, 0.369) (-1.874, -0.524) (-1.349, -0.100) 
      P-value 0.026 1.21×10
-3


















Table E4 – Distribution of covariates between adalimumab and ustekinumab treatment groups before and after inverse probability of treatment 
weighting using the propensity score 



















Baseline PASI 16.60 (6.27) 16.81 (6.50) 0.034 16.62 (6.33) 16.65 (6.36) 0.004 
Biologic naive 0.49 (0.50) 0.82 (0.39) 0.715 0.69 (0.46) 0.69 (0.46) 0.005 
Age of psoriasis onset 22.38 (12.44) 21.53 (11.63) 0.071 21.77 (11.98) 21.82 (11.83) 0.004 
Disease duration at treatment start 23.91 (12.50) 22.82 (11.51) 0.091 23.40 (12.31) 23.30 (11.71) 0.009 
Psoriatic arthritis 0.24 (0.42) 0.30 (0.45) 0.138 0.25 (0.42) 0.27 (0.44) 0.046 
Methotrexate co-therapy at treatment start 0.09 (0.29) 0.12 (0.33) 0.095 0.09 (0.29) 0.12 (0.32) 0.069 
HLA-C*06:02 dosage 0.57 (0.56) 0.56 (0.57) 0.007 0.58 (0.56) 0.57 (0.56) 0.015 
PC1 -0.00 (0.02) -0.00 (0.02) 0.022 -0.00 (0.02) -0.00 (0.02) 0.004 
PC2 -0.00 (0.02) 0.00 (0.02) 0.029 -0.00 (0.02) 0.00 (0.02) 0.043 
PC3 -0.00 (0.02) 0.00 (0.02) 0.050 -0.00 (0.02) 0.00 (0.02) 0.057 
PC4 -0.00 (0.02) -0.00 (0.02) 0.012 0.00 (0.02) -0.00 (0.02) 0.024 
















Table E5 – Significant interaction of drug and HLA-C*06:02 status in achievement of PASI75, PASI90 and PASI100 response based on inverse probability 
of treatment weighting using the propensity score 
 
 
PASI75 response PASI90 response PASI100 response 
Interaction term 3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
Drug × BL PASI 
         
      Effect size (beta) -0.025 0.038 -0.075 -0.067 0.047 -0.022 -0.030 0.052 0.012 
      95% CI (-0.105, 0.055) (-0.028, 0.105) (-0.149, -0.001) (-0.137, 0.003) (-0.006, 0.100) (-0.080, 0.035) (-0.097, 0.037) (-0.001, 0.105) (-0.045, 0.069) 
      P-value 0.542 0.258 0.049 0.062 0.082 0.441 0.379 0.056 0.683 
Drug × Age of Onset 
         
      Effect size (beta) 0.006 -0.008 0.003 0.010 -0.008 0.006 0.031 0.011 0.000 
      95% CI (-0.030, 0.043) (-0.042, 0.026) (-0.037, 0.042) (-0.027, 0.047) (-0.037, 0.021) (-0.026, 0.037) (-0.014, 0.077) (-0.026, 0.048) (-0.036, 0.036) 
      P-value 0.733 0.649 0.896 0.591 0.595 0.722 0.177 0.561 0.986 
Drug × Disease Duration 
         
      Effect size (beta) 0.028 0.000 0.003 0.021 -0.019 0.005 0.034 0.015 0.005 
      95% CI (-0.008, 0.063) (-0.032, 0.033) (-0.032, 0.038) (-0.016, 0.057) (-0.049, 0.011) (-0.027, 0.038) (-0.011, 0.079) (-0.024, 0.054) (-0.032, 0.042) 
      P-value 0.131 0.987 0.851 0.270 0.205 0.747 0.141 0.458 0.788 
Drug × PsA 
         
      Effect size (beta) -0.719 0.602 0.846 -0.310 0.128 0.912 -1.082 -0.258 0.588 
      95% CI (-1.555, 0.117) (-0.132, 1.336) (0.008, 1.685) (-1.240, 0.620) (-0.589, 0.846) (0.150, 1.673) (-2.133, -0.030) (-1.156, 0.640) (-0.266, 1.442) 
      P-value 0.092 0.108 0.048 0.513 0.726 0.019 0.044 0.573 0.178 
HLA-C*06:02 × PsA 
         
      Effect size (beta) -0.431 0.073 0.126 -0.774 -0.055 0.394 -0.409 -0.203 0.062 
      95% CI (-1.156, 0.293) (-0.572, 0.718) (-0.593, 0.846) (-1.492, -0.057) (-0.672, 0.562) (-0.233, 1.021) (-1.230, 0.411) (-0.906, 0.499) (-0.619, 0.744) 















HLA-C*06:02 × Biologic Naive 
         
      Effect size (beta) -0.134 0.426 0.372 -0.347 0.070 0.173 -0.320 -0.124 -0.114 
      95% CI (-0.825, 0.558) (-0.212, 1.064) (-0.302, 1.045) (-1.085, 0.391) (-0.528, 0.668) (-0.457, 0.803) (-1.207, 0.566) (-0.871, 0.623) (-0.827, 0.599) 
      P-value 0.705 0.191 0.280 0.357 0.818 0.591 0.479 0.744 0.754 
Drug × HLA-C*06:02 
         
      Effect size (beta) -0.818 -1.205 -0.946 -0.893 -1.237 -0.988 -0.396 -1.217 -0.694 
      95% CI (-1.535, -0.100) (-1.860, -0.551) (-1.607, -0.285) (-1.616, -0.171) (-1.818, -0.656) (-1.585, -0.391) (-1.284, 0.492) (-1.911, -0.524) (-1.326, -0.063) 


























Table E6 – Association of drug type with PASI75 and PASI100 response by HLA-C*06:02 status 
 
 
PASI75 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 
HLA-C*06:02 Negative 
      
  n adalimumab 195 265 243 195 265 243 
  n ustekinumab 113 153 137 113 153 137 
        n total 308 418 380 308 418 380 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 2.206 2.583 2.069 2.215 3.595 2.063 
        95% CI (1.357, 3.585) (1.671, 3.991) (1.280, 3.346) (1.133, 4.329) (2.125, 6.082) (1.274, 3.339) 












      
  n adalimumab 206 321 271 206 321 271 
  n ustekinumab 132 172 161 132 172 161 
        n total 338 493 432 338 493 432 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 1.171 1.055 1.146 1.325 0.963 0.931 
        95% CI (0.726, 1.890) (0.697, 1.598) (0.728, 1.803) (0.758, 2.315) (0.627, 1.479) (0.597, 1.451) 

















Table E7 – HLA-C*06:02 genotype associates with response to either drug 
Statistics relate to HLA-C*06:02 dosage term in separate multivariable models for response to adalimumab and ustekinumab. Other model covariates (ancestry PCs 1-5, 
baseline PASI, age of psoriasis onset, presence of psoriatic arthritis, biologic naive status, disease duration at treatment start and methotrexate co-therapy up to the 





3 months 6 months 12 months 3 months 6 months 12 months 
n 401 586 514 245 325 298 
HLA-C*06:02 main effect: PASI75 response 
      
      Effect size (OR) 1.059 0.775 0.802 2.624 1.856 1.675 
      95% CI (0.690, 1.625) (0.544, 1.104) (0.543, 1.183) (1.530, 4.499) (1.151, 2.993) (0.997, 2.813) 
      P-value 0.793 0.158 0.266 4.53×10
-4
 0.011 0.051 
HLA-C*06:02 main effect: PASI90 response 
      
      Effect size (OR) 0.972 0.544 0.782 2.702 1.722 1.864 
      95% CI (0.653, 1.447) (0.397, 0.747) (0.563, 1.085) (1.520, 4.804) (1.098, 2.699) (1.170, 2.970) 







HLA-C*06:02 main effect: PASI100 response 
      
      Effect size (OR) 0.952 0.608 0.700 1.707 2.011 1.325 
      95% CI (0.601, 1.507) (0.429, 0.863) (0.490, 1.001) (0.863, 3.374) (1.157, 3.496) (0.802, 2.189) 
      P-value 0.834 5.35×10
-3

















Table E8 – Association of drug type with PASI75 and PASI100 response by HLA-C*06:02 and psoriatic arthritis status 
 
 
PASI75 response PASI100 response 
 
3 months 6 months 12 months 3 months 6 months 12 months 
HLA-C*06:02 Negative without PsA 
      
  n adalimumab 124 159 160 124 159 160 
  n ustekinumab 83 109 93 83 109 93 
        n total 207 268 253 207 268 253 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 1.754 2.025 1.714 1.933 2.590 1.555 
        95% CI (0.984, 3.125) (1.178, 3.482) (0.936, 3.139) (0.877, 4.260) (1.387, 4.838) (0.882, 2.743) 
        P-value 0.057 0.011 0.081 0.102 2.83×10
-3
 0.128 
HLA-C*06:02 Negative with PsA 
      
  n adalimumab 66 100 79 66 100 79 
  n ustekinumab 26 38 39 26 38 39 
        n total 92 138 118 92 138 118 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 5.329 4.841 3.281 4.142 8.866 4.436 
        95% CI (1.946, 14.593) (2.171, 10.793) (1.419, 7.590) (0.876, 19.583) (2.550, 30.821) (1.560, 12.614) 











HLA-C*06:02 Positive without PsA 
      
  n adalimumab 150 231 198 150 231 198 
  n ustekinumab 91 128 115 91 128 115 
        n total 241 359 313 241 359 313 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 1.800 0.867 0.816 1.867 0.980 0.766 
        95% CI (1.002, 3.236) (0.529, 1.420) (0.470, 1.418) (0.947, 3.677) (0.591, 1.624) (0.454, 1.290) 















HLA-C*06:02 Positive with PsA 
      
  n adalimumab 47 82 65 47 82 65 
  n ustekinumab 35 37 41 35 37 41 
        n total 82 119 106 82 119 106 
  Drug: adalimumab vs ustekinumab 
      
        Odds ratio 0.422 1.767 2.331 0.585 0.919 1.576 
        95% CI (0.162, 1.097) (0.771, 4.049) (0.963, 5.644) (0.189, 1.808) (0.380, 2.220) (0.634, 3.919) 















Table E9 – Joint association of drug and biologic naive status with response 
Results based on simple model that includes drug and biologic naive status terms, fitted using the full cohort of 1,326 patients (controlling for baseline PASI; no other 
covariate terms and in particular no interaction terms). 
 
 
PASI75 response PASI90 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 401 586 514 401 586 514 401 586 514 
n ustekinumab 245 325 298 245 325 298 245 325 298 
      n total 646 911 812 646 911 812 646 911 812 
Drug: adalimumab vs ustekinumab       
      Effect size (beta) 0.262 0.311 0.218 0.442 0.204 -0.097 0.405 0.329 0.162 
      95% CI (-0.104, 0.627) (-0.002, 0.625) (-0.129, 0.566) (0.070, 0.813) (-0.088, 0.496) (-0.407, 0.214) (-0.051, 0.860) (-0.012, 0.671) (-0.177, 0.501) 
      P-value 0.160 0.052 0.218 0.020 0.171 0.541 0.082 0.058 0.350 
Biologic naive status       
      Effect size (beta) 0.535 0.572 0.691 0.483 0.650 0.806 0.276 0.834 0.562 
      95% CI (0.158, 0.911) (0.249, 0.895) (0.337, 1.045) (0.087, 0.880) (0.337, 0.963) (0.472, 1.141) (-0.207, 0.759) (0.441, 1.227) (0.184, 0.939) 

































PASI 90 response 
 
Biologic naive Biologic experienced 
  3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 331 477 417 70 109 97 
      adalimumab responders 148 (44.7%) 253 (53.0%) 221 (53.0%) 20 (28.6%) 37 (33.9%) 36 (37.1%) 
n ustekinumab 113 170 157 132 155 141 
      ustekinumab responders 36 (31.9%) 78 (45.9%) 91 (58.0%) 33 (25.0%) 52 (33.5%) 48 (34.0%) 
n total 444 647 574 202 264 238 
Drug × BL PASI interaction 
      
      Effect size (beta) -0.091 0.047 -0.056 -0.002 0.064 0.045 
      95% CI (-0.179, -0.003) (-0.007, 0.102) (-0.138, 0.026) (-0.137, 0.132) (-0.035, 0.164) (-0.056, 0.147) 
      P-value 0.042 0.088 0.182 0.972 0.203 0.380 
Drug × Age of Onset interaction 
      
      Effect size (beta) 0.007 -0.013 0.005 0.028 0.012 -0.002 
      95% CI (-0.040, 0.054) (-0.048, 0.022) (-0.031, 0.041) (-0.047, 0.103) (-0.047, 0.071) (-0.064, 0.061) 
      P-value 0.766 0.469 0.799 0.463 0.697 0.962 
Drug × Disease Duration interaction 
      
      Effect size (beta) -0.002 -0.025 0.003 0.049 0.000 0.002 
      95% CI (-0.049, 0.045) (-0.061, 0.012) (-0.035, 0.040) (-0.019, 0.118) (-0.059, 0.059) (-0.055, 0.059) 
      P-value 0.935 0.182 0.890 0.157 0.992 0.949 
Drug × PsA interaction 
      
      Effect size (beta) -0.424 -0.027 1.419 -0.172 0.350 -0.136 
      95% CI (-1.803, 0.954) (-1.050, 0.996) (0.375, 2.462) (-1.902, 1.559) (-0.991, 1.690) (-1.423, 1.151) 
      P-value 0.546 0.959 7.71×10
-3















HLA-C*06:02 × PsA interaction 
      
      Effect size (beta) -0.834 0.088 0.349 -1.377 -1.031 0.298 
      95% CI (-1.728, 0.059) (-0.581, 0.757) (-0.381, 1.079) (-2.735, -0.019) (-2.235, 0.174) (-0.787, 1.383) 
      P-value 0.067 0.796 0.349 0.047 0.093 0.590 
Drug × HLA-C*06:02 interaction 
      
      Effect size (beta) -0.655 -1.479 -0.963 -1.010 -1.038 -0.940 
      95% CI (-1.594, 0.284) (-2.189, -0.768) (-1.673, -0.253) (-2.484, 0.464) (-2.224, 0.148) (-2.071, 0.190) 




















Table E11 – Association of drug type with PASI90 response by HLA-C*06:02 and psoriatic arthritis status in biologic naive and biologic experienced 
subgroups 
N/A confidence interval for HLA-C*06:02 negative and biologic naive patients with PsA at 3m is due to zero (of five) observed responders to ustekinumab. 
 
 
All Subgroup without PsA Subgroup with PsA 
 
3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
HLA-C*06:02 Negative and biologic 
naive          
  n adalimumab 161 215 194 105 126 128 51 83 62 
  n ustekinumab 54 77 69 46 65 56 5 8 11 
        n total 215 292 263 151 191 184 56 91 73 
  Drug: adalimumab vs ustekinumab 
         
        Odds ratio 3.047 3.119 1.406 2.463 2.482 1.142 3.60×10
7
 14.452 4.418 
        95% CI (1.444, 6.427) (1.802, 5.400) (0.805, 2.458) (1.093, 5.550) (1.322, 4.662) (0.601, 2.172) N/A (1.680, 124.3) (1.056, 18.492) 




 0.231 0.030 4.70×10
-3
 0.684 0.992 0.015 0.042 
HLA-C*06:02 Positive and biologic 
naive          
  n adalimumab 170 262 223 124 189 166 38 66 50 
  n ustekinumab 59 93 88 42 71 64 13 16 19 
        n total 229 355 311 166 260 230 51 82 69 
  Drug: adalimumab vs ustekinumab 
         
        Odds ratio 1.154 0.669 0.470 1.514 0.857 0.314 0.469 0.282 1.008 
        95% CI (0.629, 2.116) (0.415, 1.077) (0.278, 0.796) (0.736, 3.117) (0.495, 1.482) (0.167, 0.592) (0.125, 1.766) (0.082, 0.967) (0.332, 3.061) 
        P-value 0.644 0.098 4.93×10
-3
 0.260 0.580 3.42×10
-4
 0.263 0.044 0.989 
HLA-C*06:02 Negative and biologic 
experienced          
  n adalimumab 34 50 49 19 33 32 15 17 17 
  n ustekinumab 59 76 68 37 44 37 21 30 28 















  Drug: adalimumab vs ustekinumab 
         
        Odds ratio 1.817 1.570 1.773 1.495 1.381 1.831 2.233 1.810 1.466 
        95% CI (0.618, 5.347) (0.708, 3.479) (0.781, 4.025) (0.356, 6.288) (0.505, 3.773) (0.626, 5.355) (0.412, 12.103) (0.473, 6.929) (0.359, 5.985) 
        P-value 0.278 0.267 0.171 0.583 0.529 0.269 0.351 0.386 0.594 
HLA-C*06:02 Positive and biologic 
experienced          
  n adalimumab 36 59 48 26 42 32 9 16 15 
  n ustekinumab 73 79 73 49 57 51 22 21 22 
        n total 109 138 121 75 99 83 31 37 37 
  Drug: adalimumab vs ustekinumab 
         
        Odds ratio 1.010 0.769 0.921 0.996 0.693 0.801 1.290 1.076 0.785 
        95% CI (0.432, 2.365) (0.373, 1.588) (0.430, 1.976) (0.373, 2.656) (0.303, 1.582) (0.318, 2.018) (0.182, 9.133) (0.167, 6.938) (0.168, 3.672) 

















Table E12 – HLA alleles with strongest evidence for interaction with drug 
Based on full GxE model including clinical covariates and interaction terms. The ten most strongly associated HLA alleles are reported for each combination of outcome 
(PASI75, PASI90, PASI100) and time-point. “Interaction p-value”: p-value of HLA allele dosage × Drug interaction term; “Conditional on HLA-C*06:02”: the p-value for the 
same interaction term in a model that also includes HLA-C*06:02 main effect and interaction terms. *: P < 0.05; **: P < 0.005; **: P < 1.17×10
-4
 (Bonferroni multiple testing 
threshold for 142 alleles × 3 time-points = 426 tests). Table entries for HLA-C*06:02 are highlighted in bold underlined font; note that HLA-C*06:02 is not among the top ten 
alleles for PASI100 response at 3m. 
 
 













































*0.010 *0.011 HLA-B*55:01 *0.039 *0.024 
3 months HLA-C*04 *0.019 *0.047 HLA-B*35 *0.011 *0.015 HLA-DRB1*04 *0.049 *0.044 
 
HLA-C*04:01 *0.019 *0.047 HLA-DRB1*01 *0.013 *0.013 HLA-DPB1*04:02 0.054 *0.045 
 
HLA-DRB1*13:02 *0.026 *0.012 HLA-DQB1*05 *0.014 *0.010 HLA-DQB1*06 0.086 0.052 
 
HLA-C*06:02 *0.026 N/A HLA-C*06:02 *0.017 N/A HLA-DRB1*13 0.089 0.060 
 




























 N/A HLA-C*06:02 ***3.76×10
-5
































6 months HLA-DRB1*07 *8.86×10
-3































































 0.056 HLA-B*57 **1.14×10
-3


































*0.011 0.083 HLA-B*57:01 **2.59×10
-3
 0.083 HLA-DRB1*13:01 *0.029 *0.021 
 
HLA-C*06:02 *0.012 N/A HLA-DPA1*01:03 *0.016 *0.012 HLA-B*27 *0.042 *0.033 
 





HLA-C*04:01 *0.032 0.063 HLA-DPA1*02 *0.032 *0.023 HLA-DRB1*07 *0.046 0.212 
 

















Table E13 – HLA alleles with strongest evidence for interaction with drug independently of HLA-C*06:02 
Based on full GxE model including clinical covariates and interaction terms, plus HLA-C*06:02 main effect and interaction terms. The ten most strongly associated HLA 
alleles are reported for each combination of outcome (PASI75, PASI90, PASI100) and time-point. *: P < 0.05; **: P < 0.005; no tests achieved P < 1.17×10
-4
 (Bonferroni 
multiple testing threshold for 142 alleles × 3 time-points = 426 tests). 
 
 


























 HLA-DQB1*05 *0.010 HLA-B*37 *0.036 
 
HLA-DRB1*13:02 *0.012 HLA-DQB1*05:01 *0.011 HLA-B*37:01 *0.036 
3 months HLA-DQB1*05:01 *0.012 HLA-C*04:01 *0.013 HLA-DRB1*04 *0.044 
 
HLA-DPB1*13 *0.044 HLA-C*04 *0.013 HLA-DPB1*04:02 *0.045 
 
HLA-DPB1*13:01 *0.044 HLA-DRB1*13 *0.013 HLA-DQB1*03:01 *0.045 
 
HLA-DQB1*03:01 *0.045 HLA-DRB1*01 *0.013 HLA-DQB1*06 0.052 
 
HLA-C*04 *0.047 HLA-B*44:02 *0.015 HLA-DRB1*13 0.060 
 












HLA-DRB1*01 *0.015 HLA-DPB1*10:01 *0.037 HLA-DRB1*01:03 0.066 
 
HLA-C*01:02 *0.018 HLA-DPB1*10 *0.037 HLA-DRB1*15:01 0.090 
 
HLA-DQB1*05:01 *0.019 HLA-A*29 0.058 HLA-DRB1*15 0.091 
 
HLA-DQA1*01:01 *0.021 HLA-A*30:01 0.063 HLA-B*27 0.092 
6 months HLA-DQB1*05 *0.022 HLA-A*30 0.069 HLA-DQB1*06:02 0.093 
 
HLA-DQA1*01 *0.027 HLA-B*57 0.082 HLA-B*27:05 0.102 
 
HLA-DRB1*01:01 *0.038 HLA-DRB1*01:03 0.087 HLA-A*29:02 0.102 
 
















HLA-DQB1*03 0.055 HLA-DQB1*06:02 0.095 HLA-A*29 0.105 
 


















HLA-B*13:02 *0.017 HLA-B*39 *5.54×10
-3
 HLA-DRB1*13:01 *0.021 
 
HLA-DQB1*03:01 *0.017 HLA-C*12:03 *7.79×10
-3
 HLA-B*27 *0.033 
 
HLA-B*13 *0.022 HLA-DPA1*01:03 *0.012 HLA-B*27:05 *0.037 
12 months HLA-C*12 *0.027 HLA-C*02:02 *0.022 HLA-DQA1*01:03 *0.038 
 
HLA-DQB1*06 *0.029 HLA-DPA1*01 *0.023 HLA-DQB1*06:03 *0.041 
 
HLA-B*57:01 *0.031 HLA-DPA1*02 *0.023 HLA-DQB1*03:01 *0.042 
 
HLA-DRB1*04:01 *0.048 HLA-B*57 *0.035 HLA-DPA1*02:02 0.055 
 
HLA-DQA1*01:02 0.053 HLA-DPA1*02:02 *0.040 HLA-A*31:01 0.058 
 

















Table E14 – Full drug × HLA allele interaction test results for all HLA alleles 
 
















Table E15 – GxGxE test results for interaction between HLA-C*06:02 and ERAP1 variant rs27524 
Based on full GxGxE model including the second-order interaction term drug × HLA-C*06:02 dosage × rs27524 genotype, all lower-order interaction and main-effect terms, 
and all covariates from the full GxE model. Results shown are for first- and second-order interaction terms between drug, HLA-C*06:02 dosage and rs27524 genotype only. 
 
PASI75 response PASI90 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 401 586 514 401 586 514 401 586 514 
n ustekinumab 245 325 298 245 325 298 245 325 298 
      n total 646 911 812 646 911 812 646 911 812 
Drug × HLA-C*06:02 interaction 
         
      Effect size (beta) -1.201 -0.649 -0.744 -0.634 -1.304 -0.674 -0.419 -1.195 -0.597 
      95% CI (-2.274, -0.127) (-1.559, 0.262) (-1.713, 0.225) (-1.700, 0.432) (-2.140, -0.469) (-1.499, 0.151) (-1.722, 0.884) (-2.182, -0.207) (-1.513, 0.318) 
      P-value 0.028 0.163 0.132 0.243 2.22×10
-3
 0.109 0.528 0.018 0.201 
Drug × rs27524 interaction 
         
      Effect size (beta) -0.751 0.301 -0.101 0.092 -0.017 -0.209 -0.410 -0.234 -0.264 
      95% CI (-1.484, -0.019) (-0.370, 0.972) (-0.844, 0.642) (-0.746, 0.929) (-0.655, 0.622) (-0.871, 0.453) (-1.389, 0.569) (-1.013, 0.545) (-0.986, 0.458) 
      P-value 0.044 0.379 0.789 0.830 0.959 0.536 0.412 0.556 0.473 
HLA-C*06:02 × rs27524 interaction 
         
      Effect size (beta) -0.422 0.314 0.090 0.078 -0.331 0.053 0.027 -0.109 0.060 
      95% CI (-1.177, 0.333) (-0.370, 0.998) (-0.636, 0.815) (-0.723, 0.879) (-0.985, 0.323) (-0.597, 0.703) (-0.904, 0.957) (-0.902, 0.683) (-0.648, 0.768) 
      P-value 0.274 0.368 0.809 0.848 0.321 0.873 0.955 0.787 0.868 
Drug × HLA-C*06:02 × rs27524 
interaction          
      Effect size (beta) 0.585 -0.506 -0.131 -0.312 0.090 -0.259 0.028 0.013 -0.102 
      95% CI (-0.339, 1.509) (-1.343, 0.332) (-1.039, 0.777) (-1.257, 0.632) (-0.702, 0.883) (-1.059, 0.540) (-1.066, 1.122) (-0.923, 0.949) (-0.971, 0.767) 
















Table E16 – GxE model for drug and ERAP1 genotype among patients that are HLA-C*06:02 negative 
Based on GxE model for patients that are HLA-C*06:02 negative only. Results are presented for the model interaction term only. Results for other model terms are not 
shown; in particular main effect terms are not unambiguously interpretable in the presence of an interaction term. 
 
 
PASI75 response PASI90 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
HLA-C*06:02 Negative 
         
  n adalimumab 195 265 243 195 265 243 195 265 243 
  n ustekinumab 113 153 137 113 153 137 113 153 137 
        n total 308 418 380 308 418 380 308 418 380 
  Drug × rs27524 interaction 
         
        Effect size (beta) -0.893 0.082 -0.346 0.166 -0.109 -0.319 -0.410 -0.356 -0.314 
        95% CI (-1.644, -0.142) (-0.594, 0.758) (-1.086, 0.393) (-0.732, 1.064) (-0.771, 0.552) (-0.986, 0.349) (-1.437, 0.616) (-1.171, 0.459) (-1.049, 0.422) 
















Table E17 – Test results for HLA-C*06:02 and ERAP1 model excluding GxGxE term 
Based on model including same main effect and first-order interaction terms as the full GxGxE model, but no second-order interaction term. Results shown are for 
interaction terms between drug, HLA-C*06:02 dosage and rs27524 genotype only. 
 
PASI75 response PASI90 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 401 586 514 401 586 514 401 586 514 
n ustekinumab 245 325 298 245 325 298 245 325 298 
      n total 646 911 812 646 911 812 646 911 812 
Drug × HLA-C*06:02 interaction 
         
      Effect size (beta) -0.722 -1.051 -0.845 -0.886 -1.235 -0.863 -0.395 -1.185 -0.675 
      95% CI (-1.470, 0.025) (-1.680, -0.422) (-1.522, -0.167) (-1.639, -0.133) (-1.813, -0.657) (-1.451, -0.275) (-1.292, 0.502) (-1.866, -0.504) (-1.308, -0.043) 







Drug × rs27524 interaction 
         
      Effect size (beta) -0.440 0.010 -0.177 -0.115 0.037 -0.363 -0.392 -0.226 -0.324 
      95% CI (-0.979, 0.098) (-0.454, 0.473) (-0.703, 0.349) (-0.668, 0.439) (-0.397, 0.470) (-0.825, 0.098) (-1.054, 0.270) (-0.740, 0.287) (-0.832, 0.183) 
      P-value 0.109 0.968 0.510 0.685 0.868 0.123 0.246 0.388 0.210 
HLA-C*06:02 × rs27524 interaction 
         
      Effect size (beta) -0.030 -0.022 0.007 -0.145 -0.270 -0.118 0.047 -0.100 -0.007 
      95% CI (-0.470, 0.409) (-0.417, 0.372) (-0.435, 0.448) (-0.572, 0.281) (-0.642, 0.102) (-0.498, 0.263) (-0.449, 0.543) (-0.524, 0.323) (-0.422, 0.407) 
















Table E18 – GxE test results for which duplicated patients are excluded from both groups 
Results of fitting the simple GxE model including covariate terms for baseline PASI, five ancestry PCs, drug, HLA-C*06:02 dosage and the drug × HLA-C*06:02 interaction, 
after excluding 101 patients that were randomly allocated to adalimumab/ustekinumab groups due to having eligible records for both. Results are comparable to main 
findings shown in Table E2. 
 
 
PASI75 response PASI90 response PASI100 response 
  3 months 6 months 12 months 3 months 6 months 12 months 3 months 6 months 12 months 
n adalimumab 379 548 489 379 548 489 379 548 489 
n ustekinumab 216 294 268 216 294 268 216 294 268 
      n total 595 842 757 595 842 757 595 842 757 
Drug × HLA-C*06:02 interaction 
         
      Effect size (beta) -0.794 -0.972 -0.846 -1.108 -1.177 -0.813 -0.794 -1.227 -0.804 
      95% CI (-1.454, -0.135) (-1.560, -0.384) (-1.476, -0.216) (-1.802, -0.414) (-1.718, -0.636) (-1.360, -0.266) (-1.612, 0.024) (-1.873, -0.582) (-1.405, -0.204) 
































Genotype data and HLA imputation 
DNA was isolated from blood using standard methods. Genotyping was performed using Illumina 
HumanOmniExpressExome-8 v1.2 and v1.3 BeadChips. Three rounds of genotype calling were 
performed using Illumina’s GenomeStudio Data Analysis software, based on four different 
genotyping batches (samples clustered using GenTrain 2.0 algorithm). Genotyping QC was 






. Samples were excluded based on call rate (<0.99), 
mismatch with recorded gender, heterozygosity (±4 s.d. from the mean), relatedness (second degree 
relative or closer; kinship coefficient > 0.0884), suspected non-European ancestry indicated by 
principal component analysis (PCA) and residual PCA outlier status (>5 s.d. from the mean for PCs 1-
20). Genetic variants were excluded based on call rate (<0.99), low GenomeStudio cluster separation 
score (<0.4), deviations from Hardy-Weinberg equilibrium (P < 7.5×10
-8
 based on number of variants 
tested) and minor allele frequency <1%. To eliminate potential batch effects we checked that there 
were no allele flips between batches and excluded variants with differential missing rates (P < 0.01) 
and allele frequencies (P < 10
-5
; 7 variants) between batches. 
HLA imputation proceeded as follows. First, genotype intensity cluster plots were inspected 
for 3,141 single nucleotide polymorphisms in the HLA region (all SNPs within the range 
chr6:29494897-33160425 in the GRCh37/hg19 genome assembly, to correspond to the imputation 
reference panel described below). Where appropriate, genotypes were manually “rescued” using 
Evoker (version 2.3)
4
. Classical HLA alleles were imputed using SNP2HLA (v1.0.3), based on the 
T1DGC reference panel
5
. We excluded poorly imputed alleles (R2 < 0.9) and alleles with frequency 
<0.01, giving a total of 142 distinct 2- and 4-digit imputed alleles. 
 
Statistical modelling 
To generate the full multivariable logistic regression model for response accounting for potential 
clinical confounders, main effect and interaction covariate terms were added based on correlations 
with HLA-C*06:02 or drug (Table 1). For variables significantly correlated with HLA-C*06:02, an 
interaction term with drug was included, and vice versa. 
The full model included: covariate main effect terms for baseline PASI, ancestry PCs 1-5 
derived from 108,319 independent SNPs using KING software
2
, age of psoriasis onset, presence of 
PsA, biologic naive status, disease duration at treatment start, and methotrexate co-therapy up to 















baseline PASI, disease duration and PsA; and interaction terms with HLA-C*06:02 dosage for PsA and 
biologic naive status 
 
Propensity score modelling 
To confirm that our full multivariable model adequately controlled for potential confounding via 
covariates influencing treatment selection, we repeated the regression analysis with inverse 
probability of treatment weighting (IPTW) using the propensity score
6
. Specifically, we derived a 
propensity score model to estimate the probability that each patient would have been received 
treatment with adalimumab rather than ustekinumab. As recommended by Austin
6
, we included in 
the propensity score model all “potential confounders”: covariates that were independently 
associated with PASI90 response. Conservatively, we included all covariates that demonstrated a 
nominal association with PASI90 response (P < 0.05) at any of our three time-points, among 
adalimumab patients only, ustekinumab patients only, or all patients combined (data not shown). 
The propensity score model included baseline PASI, ancestry PC 1, age of psoriasis onset, presence 
of PsA, biologic naive status, disease duration at treatment start and HLA-C*06:02 dosage. Balance 
analysis showed that all covariates were well matched between adalimumab and ustekinumab 
groups after IPTW using the propensity score (Table E4, Figure E1): all standardised mean 
differences were below the accepted threshold of 0.1 at which a covariate differences between 
groups can be considered negligible
6
. 
IPTW can be incorporated into regression models analogously to survey sampling weights. 
The full multivariable logistic regression model (described in the previous section) was re-fitted using 
IPTW derived from the propensity score model using the ‘survey’ package in R.  
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Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P Beta SE P
HLA-A*01 -0.4364 0.3263 0.1812 -0.3026 0.3390 0.3722 -0.1708 0.2717 0.5296 -0.0347 0.2799 0.9012 -0.3408 0.3099 0.2716 -0.2145 0.3198 0.5024 0.0401 0.3206 0.9004 0.2727 0.3354 0.4163 -0.0654 0.2529 0.7958 0.1264 0.2600 0.6267 -0.2741 0.2744 0.3179 -0.1279 0.2825 0.6507 0.0536 0.3917 0.8912 0.2004 0.4044 0.6202 -0.3282 0.2945 0.2651 -0.1446 0.3004 0.6303 -0.0707 0.2968 0.8118 0.0482 0.3033 0.8736
HLA-A*01:01 -0.4334 0.3264 0.1842 -0.2993 0.3391 0.3774 -0.1599 0.2716 0.5559 -0.0248 0.2797 0.9293 -0.3300 0.3097 0.2866 -0.2042 0.3195 0.5228 0.0451 0.3208 0.8881 0.2781 0.3356 0.4073 -0.0492 0.2531 0.8459 0.1422 0.2601 0.5845 -0.2849 0.2744 0.2991 -0.1418 0.2823 0.6154 0.0524 0.3917 0.8936 0.1993 0.4044 0.6222 -0.3327 0.2944 0.2585 -0.1514 0.3002 0.6142 -0.0795 0.2966 0.7887 0.0374 0.3030 0.9019
HLA-A*02 -0.1009 0.3087 0.7439 -0.1263 0.3185 0.6917 -0.1891 0.2565 0.4611 -0.2398 0.2614 0.3590 0.2060 0.2827 0.4662 0.2050 0.2856 0.4730 -0.1214 0.3129 0.6980 -0.1453 0.3190 0.6487 -0.1213 0.2355 0.6066 -0.1612 0.2387 0.4994 -0.0965 0.2428 0.6910 -0.1129 0.2457 0.6458 0.3106 0.3873 0.4226 0.3059 0.3868 0.4290 -0.1182 0.2778 0.6705 -0.1777 0.2808 0.5268 0.1324 0.2668 0.6198 0.1222 0.2676 0.6479
HLA-A*02:01 -0.0208 0.3123 0.9469 -0.0385 0.3201 0.9043 -0.1314 0.2556 0.6073 -0.1736 0.2600 0.5044 0.2469 0.2840 0.3847 0.2437 0.2864 0.3947 -0.0785 0.3156 0.8034 -0.1031 0.3224 0.7491 -0.0539 0.2358 0.8191 -0.0902 0.2388 0.7056 -0.0613 0.2441 0.8019 -0.0783 0.2466 0.7509 0.4310 0.3950 0.2752 0.4313 0.3974 0.2778 -0.0482 0.2791 0.8630 -0.1028 0.2821 0.7156 0.1049 0.2680 0.6956 0.0918 0.2690 0.7330
HLA-A*03 0.2413 0.5011 0.6301 0.3166 0.5109 0.5354 -0.1436 0.4605 0.7552 -0.1127 0.4630 0.8077 -0.6857 0.5503 0.2128 -0.6800 0.5537 0.2194 -0.0245 0.5238 0.9628 -0.0081 0.5352 0.9880 0.2410 0.3980 0.5448 0.2525 0.4021 0.5300 -0.1345 0.3918 0.7314 -0.1613 0.3938 0.6821 -0.2410 0.6029 0.6894 -0.2396 0.6088 0.6939 0.5780 0.4983 0.2461 0.6475 0.5065 0.2011 0.2078 0.4510 0.6450 0.1660 0.4526 0.7138
HLA-A*03:01 0.2417 0.5011 0.6295 0.3172 0.5110 0.5347 -0.1431 0.4607 0.7560 -0.1122 0.4632 0.8086 -0.6865 0.5507 0.2125 -0.6812 0.5540 0.2188 -0.0245 0.5240 0.9627 -0.0080 0.5354 0.9881 0.2413 0.3982 0.5445 0.2530 0.4023 0.5294 -0.1413 0.3923 0.7187 -0.1685 0.3942 0.6691 -0.2430 0.6030 0.6870 -0.2415 0.6089 0.6916 0.5756 0.4985 0.2483 0.6452 0.5067 0.2029 0.2125 0.4510 0.6375 0.1713 0.4526 0.7052
HLA-A*11 0.6584 0.6060 0.2773 0.3925 0.6238 0.5292 0.8024 0.5386 0.1363 0.7203 0.5430 0.1847 0.7592 0.6353 0.2321 0.6105 0.6494 0.3472 0.5411 0.6935 0.4353 0.2431 0.7304 0.7393 -0.4335 0.5097 0.3950 -0.5894 0.5189 0.2560 -0.7164 0.5589 0.1999 -0.9131 0.5736 0.1114 -0.1605 0.9407 0.8645 -0.4034 0.9703 0.6776 -0.5753 0.5927 0.3317 -0.7304 0.6065 0.2285 -0.7934 0.6027 0.1880 -0.9035 0.6071 0.1367
HLA-A*11:01 0.6771 0.6070 0.2647 0.4120 0.6247 0.5095 0.8042 0.5388 0.1355 0.7216 0.5431 0.1839 0.7569 0.6357 0.2338 0.6080 0.6498 0.3494 0.5706 0.6976 0.4134 0.2729 0.7343 0.7102 -0.4300 0.5099 0.3991 -0.5863 0.5191 0.2587 -0.7190 0.5591 0.1984 -0.9157 0.5738 0.1105 -0.1667 0.9399 0.8592 -0.4085 0.9693 0.6734 -0.5767 0.5929 0.3308 -0.7322 0.6068 0.2275 -0.7947 0.6028 0.1874 -0.9047 0.6072 0.1362
HLA-A*23 0.9517 1.1714 0.4165 0.9794 1.2327 0.4269 0.4912 0.9744 0.6142 0.4799 0.9881 0.6272 1.7930 1.2836 0.1625 1.7995 1.2999 0.1663 0.0904 1.1013 0.9346 0.0783 1.1423 0.9453 0.3804 0.9100 0.6759 0.3094 0.9226 0.7374 2.5677 1.3605 0.0591 2.6557 1.3703 0.0526 -0.6766 1.1351 0.5511 -0.7155 1.1427 0.5312 1.5441 1.2190 0.2053 1.4458 1.2171 0.2349 0.9640 1.4076 0.4934 0.9775 1.4137 0.4893
HLA-A*23:01 0.9515 1.1713 0.4166 0.9792 1.2327 0.4270 0.4915 0.9745 0.6140 0.4802 0.9882 0.6270 1.7935 1.2837 0.1624 1.8000 1.2999 0.1662 0.0875 1.1012 0.9366 0.0750 1.1422 0.9476 0.3805 0.9100 0.6758 0.3095 0.9226 0.7373 2.5678 1.3605 0.0591 2.6558 1.3703 0.0526 -0.6765 1.1351 0.5512 -0.7155 1.1427 0.5312 1.5442 1.2190 0.2052 1.4459 1.2171 0.2349 0.9710 1.4075 0.4903 0.9852 1.4134 0.4858
HLA-A*24 -0.6472 0.7797 0.4065 -0.7272 0.7957 0.3608 -0.2203 0.5714 0.6998 -0.4277 0.5820 0.4624 -0.2117 0.7028 0.7633 -0.2930 0.7101 0.6799 -0.2624 0.7449 0.7246 -0.3865 0.7700 0.6157 0.2983 0.5122 0.5603 0.1067 0.5192 0.8372 0.2148 0.5977 0.7193 0.1271 0.6033 0.8331 0.4809 0.9094 0.5970 0.4477 0.9284 0.6296 0.6429 0.6512 0.3235 0.5298 0.6617 0.4233 0.4303 0.6426 0.5031 0.3651 0.6431 0.5702
HLA-A*24:02 -0.7074 0.8137 0.3847 -0.7997 0.8302 0.3354 -0.2452 0.5854 0.6753 -0.4580 0.5962 0.4424 -0.1970 0.7204 0.7845 -0.2857 0.7283 0.6948 -0.2755 0.7738 0.7218 -0.4105 0.8021 0.6088 0.3255 0.5280 0.5376 0.1312 0.5347 0.8062 0.2408 0.6188 0.6972 0.1471 0.6247 0.8138 0.4557 0.9529 0.6325 0.4208 0.9766 0.6666 0.6605 0.6707 0.3247 0.5441 0.6812 0.4244 0.4488 0.6670 0.5010 0.3792 0.6675 0.5700
HLA-A*25:01 1.1730 1.0077 0.2444 0.7887 1.0098 0.4347 1.0530 0.7895 0.1823 0.9646 0.8025 0.2294 2.4761 0.9232 0.0073 2.2878 0.9296 0.0139 0.7628 1.3170 0.5625 0.2799 1.3292 0.8332 1.0797 0.8569 0.2076 0.9169 0.8586 0.2856 1.1146 0.7667 0.1460 0.9025 0.7723 0.2426 4.6393 9.7187 0.6331 4.3537 9.7579 0.6555 0.1201 1.0308 0.9072 0.0049 1.0368 0.9963 0.7431 0.9893 0.4526 0.5697 0.9973 0.5679
HLA-A*26 -0.0873 1.3806 0.9496 0.4337 1.4289 0.7615 -0.7756 1.0435 0.4573 -0.9434 1.0661 0.3762 0.5288 1.2758 0.6785 0.3014 1.3176 0.8190 -0.1303 1.2722 0.9184 0.4020 1.2659 0.7509 0.0644 1.0931 0.9530 -0.0300 1.1165 0.9786 2.0912 1.4167 0.1399 2.2509 1.4356 0.1169 -0.7449 1.3829 0.5902 -0.4758 1.3611 0.7266 -0.5359 1.1261 0.6342 -0.6350 1.1359 0.5761 23.7638 36.1474 0.5109 18.1586 36.6493 0.6203
HLA-A*26:01 -0.0759 1.3852 0.9563 0.4467 1.4335 0.7553 -0.8075 1.0535 0.4434 -0.9738 1.0766 0.3657 0.4862 1.2915 0.7066 0.2591 1.3339 0.8460 -0.1293 1.2768 0.9193 0.4044 1.2706 0.7503 0.0538 1.0985 0.9609 -0.0380 1.1220 0.9730 2.0867 1.4255 0.1432 2.2477 1.4436 0.1195 -0.7483 1.3875 0.5897 -0.4791 1.3659 0.7257 -0.5509 1.1313 0.6263 -0.6458 1.1409 0.5714 22.9945 36.7105 0.5311 17.2371 37.1250 0.6424
HLA-A*29 0.1887 0.8064 0.8149 -0.2074 0.8311 0.8029 1.1140 0.6608 0.0918 1.1039 0.6668 0.0978 0.0970 0.7841 0.9015 0.0548 0.7954 0.9451 0.2513 0.7928 0.7513 -0.0673 0.8227 0.9348 1.2781 0.6403 0.0459 1.2292 0.6486 0.0581 0.6329 0.6881 0.3577 0.6047 0.6978 0.3862 -0.0226 0.9755 0.9815 -0.1810 0.9968 0.8559 1.2866 0.7499 0.0862 1.2346 0.7606 0.1045 -0.4204 0.7358 0.5678 -0.4706 0.7339 0.5214
HLA-A*29:02 0.1509 0.8882 0.8651 -0.1137 0.9108 0.9007 0.7639 0.6905 0.2685 0.8218 0.6994 0.2400 -0.3044 0.8421 0.7177 -0.3507 0.8568 0.6824 -0.0243 0.8369 0.9768 -0.2552 0.8595 0.7665 1.1073 0.6637 0.0952 1.1056 0.6719 0.0999 0.4413 0.7082 0.5332 0.4220 0.7183 0.5568 -0.1877 1.0093 0.8525 -0.3085 1.0256 0.7636 1.3396 0.8084 0.0975 1.3283 0.8134 0.1025 -0.4835 0.7569 0.5230 -0.5246 0.7548 0.4871
HLA-A*30 0.4493 0.9081 0.6208 0.5422 0.9187 0.5551 0.2156 0.7662 0.7784 0.5077 0.7745 0.5121 -0.2217 0.7717 0.7739 0.0891 0.7892 0.9101 0.2053 0.8859 0.8167 0.3477 0.9303 0.7086 -1.6992 0.7909 0.0317 -1.4480 0.7973 0.0694 1.3284 0.8719 0.1276 1.6814 0.8877 0.0582 -0.8291 1.0396 0.4251 -0.8130 1.0529 0.4400 -1.0815 0.8431 0.1996 -0.8815 0.8485 0.2989 -0.0606 1.1440 0.9578 0.1636 1.1609 0.8879
HLA-A*30:01 -0.6127 1.4179 0.6657 0.1628 1.4098 0.9081 -0.3949 1.0123 0.6965 0.1604 1.0329 0.8766 0.1234 0.8840 0.8890 0.6396 0.9128 0.4835 -1.0782 1.2149 0.3748 -0.3942 1.2556 0.7536 -2.8164 1.2271 0.0217 -2.3191 1.2473 0.0630 1.3813 1.0705 0.1969 1.9771 1.0950 0.0710 -1.4760 1.3903 0.2884 -1.0968 1.4126 0.4375 -1.1167 1.0014 0.2648 -0.5211 1.0230 0.6105 0.3710 1.6389 0.8209 0.8435 1.6306 0.6050
HLA-A*31 0.6003 1.1548 0.6032 0.3993 1.2061 0.7406 0.1970 0.8664 0.8202 0.1644 0.8706 0.8502 -0.6966 1.1065 0.5290 -0.9513 1.1318 0.4006 -2.4099 1.4451 0.0954 -2.4101 1.4784 0.1030 0.3411 0.8823 0.6991 0.3482 0.8869 0.6946 -0.0683 1.0709 0.9491 -0.3194 1.0764 0.7667 -1.2441 1.6434 0.4490 -1.1950 1.6744 0.4754 -0.3118 1.0330 0.7628 -0.3586 1.0268 0.7269 -2.1634 1.2413 0.0814 -2.3419 1.2369 0.0583
HLA-A*31:01 0.6009 1.1546 0.6028 0.3999 1.2058 0.7401 0.1975 0.8665 0.8197 0.1650 0.8706 0.8497 -0.6936 1.1060 0.5306 -0.9487 1.1314 0.4018 -2.4074 1.4448 0.0957 -2.4076 1.4784 0.1034 0.3415 0.8823 0.6987 0.3486 0.8869 0.6943 -0.0728 1.0711 0.9458 -0.3243 1.0766 0.7633 -1.2366 1.6435 0.4518 -1.1903 1.6743 0.4771 -0.3116 1.0330 0.7629 -0.3584 1.0269 0.7271 -2.1663 1.2414 0.0810 -2.3451 1.2371 0.0580
HLA-A*32:01 0.9699 0.7782 0.2126 0.9909 0.7910 0.2103 -0.5100 0.7571 0.5006 -0.8246 0.7649 0.2810 0.1223 0.6715 0.8555 -0.0753 0.6841 0.9123 -0.0728 0.8202 0.9293 -0.1249 0.8615 0.8848 -0.3887 0.7619 0.6100 -0.6633 0.7746 0.3919 -0.0837 0.7299 0.9088 -0.2618 0.7522 0.7278 -1.1823 1.2186 0.3319 -1.1961 1.2437 0.3362 -0.3779 0.8542 0.6582 -0.6505 0.8824 0.4610 0.1093 0.7298 0.8809 0.0162 0.7373 0.9825
HLA-A*68 0.3746 1.2297 0.7606 0.3248 1.2710 0.7983 -0.2631 0.9631 0.7847 -0.2717 0.9659 0.7785 -14.6006 426.1301 0.9727 -14.6001 421.8876 0.9724 -0.1719 1.1421 0.8804 -0.4039 1.1530 0.7261 0.2224 0.7657 0.7714 0.2026 0.7766 0.7941 -1.9978 1.1797 0.0904 -2.0772 1.1938 0.0819 -0.7232 1.2951 0.5766 -0.8909 1.2609 0.4799 0.9784 0.8781 0.2652 1.0079 0.8960 0.2606 -0.6894 0.8746 0.4305 -0.6784 0.8852 0.4434
HLA-A*68:01 0.1696 1.2262 0.8900 0.0895 1.2648 0.9436 -0.4112 0.9778 0.6741 -0.4307 0.9863 0.6623 -14.7973 418.8727 0.9718 -14.7920 415.2784 0.9716 -0.2049 1.1544 0.8591 -0.4471 1.1642 0.7010 0.4055 0.8068 0.6152 0.3924 0.8170 0.6311 -2.3512 1.2096 0.0519 -2.4392 1.2237 0.0462 -0.9708 1.3503 0.4722 -1.1382 1.3125 0.3858 0.9712 0.9300 0.2964 1.0066 0.9420 0.2852 -0.9509 0.9066 0.2942 -0.9488 0.9169 0.3008
HLA-B*07 0.1648 0.4802 0.7314 0.0369 0.4900 0.9400 0.5413 0.4483 0.2272 0.3622 0.4571 0.4281 -0.0777 0.5012 0.8769 -0.2732 0.5110 0.5929 0.6705 0.5690 0.2387 0.5231 0.5852 0.3713 0.4059 0.4411 0.3575 0.2030 0.4486 0.6509 0.3863 0.4152 0.3521 0.1873 0.4236 0.6583 0.6367 0.7471 0.3941 0.5365 0.7568 0.4784 0.5360 0.5983 0.3703 0.3461 0.6086 0.5696 0.3544 0.4821 0.4623 0.2310 0.4895 0.6369
HLA-B*07:02 0.1495 0.4929 0.7617 0.0660 0.5012 0.8952 0.3761 0.4612 0.4148 0.2056 0.4698 0.6616 -0.2240 0.5165 0.6645 -0.4230 0.5269 0.4221 0.4539 0.5793 0.4332 0.3356 0.5952 0.5728 0.2557 0.4498 0.5698 0.0619 0.4577 0.8925 0.2866 0.4182 0.4932 0.0892 0.4263 0.8342 0.5052 0.7581 0.5051 0.4247 0.7664 0.5795 0.4077 0.6022 0.4984 0.2398 0.6130 0.6957 0.3180 0.4820 0.5094 0.1919 0.4891 0.6948
HLA-B*08 0.2088 0.4327 0.6294 -0.0066 0.4534 0.9884 0.1467 0.3576 0.6816 -0.1729 0.3744 0.6443 0.1489 0.4228 0.7247 -0.1305 0.4410 0.7672 0.4025 0.4688 0.3906 0.1985 0.4889 0.6847 0.0989 0.3369 0.7690 -0.2955 0.3543 0.4043 0.0085 0.3881 0.9826 -0.3135 0.4066 0.4407 0.7623 0.6681 0.2538 0.6941 0.6832 0.3096 0.1027 0.3970 0.7959 -0.2928 0.4164 0.4819 0.6776 0.4397 0.1233 0.4760 0.4530 0.2934
HLA-B*08:01 0.2088 0.4327 0.6295 -0.0066 0.4534 0.9883 0.1467 0.3576 0.6816 -0.1729 0.3744 0.6443 0.1491 0.4228 0.7244 -0.1304 0.4410 0.7675 0.4025 0.4688 0.3906 0.1985 0.4889 0.6847 0.0991 0.3369 0.7687 -0.2954 0.3543 0.4045 0.0085 0.3881 0.9825 -0.3135 0.4066 0.4407 0.7624 0.6681 0.2538 0.6941 0.6832 0.3096 0.1028 0.3970 0.7958 -0.2928 0.4164 0.4820 0.6777 0.4397 0.1233 0.4760 0.4530 0.2933
HLA-B*13 -0.9442 0.6784 0.1640 -0.3570 0.7370 0.6281 -1.2051 0.5632 0.0324 -0.6749 0.6011 0.2615 0.7366 0.5709 0.1970 1.4270 0.6210 0.0216 -0.5836 0.6320 0.3558 0.0324 0.6748 0.9617 -1.1660 0.4682 0.0128 -0.5615 0.5025 0.2638 0.3528 0.5054 0.4851 0.9697 0.5422 0.0737 0.5380 0.7451 0.4703 0.9629 0.7958 0.2263 -0.9128 0.5119 0.0746 -0.2620 0.5518 0.6349 -0.2090 0.5474 0.7027 0.2368 0.5832 0.6847
HLA-B*13:02 -0.9570 0.6817 0.1604 -0.3546 0.7388 0.6312 -1.2116 0.5632 0.0315 -0.6821 0.6009 0.2563 0.8286 0.5817 0.1543 1.5124 0.6308 0.0165 -0.5708 0.6370 0.3702 0.0546 0.6781 0.9359 -1.1822 0.4694 0.0118 -0.5806 0.5032 0.2486 0.4518 0.5177 0.3828 1.0706 0.5549 0.0537 0.6833 0.7757 0.3784 1.1201 0.8233 0.1737 -0.8983 0.5115 0.0790 -0.2506 0.5512 0.6493 -0.2345 0.5698 0.6806 0.2024 0.6034 0.7374
HLA-B*14 -0.4905 0.8245 0.5519 -0.4444 0.8462 0.5995 -0.3982 0.6817 0.5592 -0.5074 0.6874 0.4604 -0.2613 0.9393 0.7809 -0.3207 0.9293 0.7300 1.6065 1.0922 0.1413 1.8837 1.1734 0.1084 1.1415 0.6720 0.0894 1.0063 0.6813 0.1397 0.5833 0.7319 0.4255 0.4873 0.7372 0.5086 1.1252 1.0635 0.2900 1.2878 1.1096 0.2458 0.8851 0.9177 0.3348 0.7608 0.9357 0.4162 0.2114 0.8097 0.7941 0.1265 0.8229 0.8778
HLA-B*14:02 -1.0273 0.9147 0.2614 -1.1478 0.9342 0.2192 -0.9032 0.8709 0.2997 -1.0997 0.8796 0.2112 -2.5171 1.5958 0.1147 -2.6120 1.5769 0.0976 1.7724 1.3493 0.1890 1.8890 1.4232 0.1844 1.1018 0.8262 0.1824 0.8724 0.8412 0.2997 1.0083 0.8919 0.2583 0.8445 0.9006 0.3484 1.2259 1.3275 0.3558 1.3290 1.3794 0.3353 1.3139 1.2147 0.2794 1.0284 1.2275 0.4022 1.3560 1.2196 0.2662 1.2175 1.2285 0.3217
HLA-B*15 0.2732 0.5312 0.6070 0.1798 0.5501 0.7437 0.8377 0.4869 0.0853 0.6761 0.4961 0.1729 -0.1056 0.5918 0.8584 -0.2656 0.6040 0.6601 0.3112 0.5586 0.5775 0.1769 0.5792 0.7601 0.2677 0.4433 0.5460 0.0303 0.4515 0.9465 -0.3711 0.4992 0.4572 -0.5646 0.5097 0.2679 -0.1385 0.6221 0.8238 -0.2286 0.6346 0.7187 0.1226 0.5193 0.8133 -0.1239 0.5294 0.8149 -0.2288 0.5306 0.6663 -0.3761 0.5357 0.4826
HLA-B*15:01 0.7181 0.5909 0.2242 0.7119 0.6117 0.2446 0.7102 0.5271 0.1779 0.6065 0.5354 0.2573 0.3927 0.6609 0.5524 0.2497 0.6748 0.7113 0.5046 0.6104 0.4085 0.4347 0.6298 0.4900 0.3729 0.4915 0.4480 0.2025 0.4986 0.6847 -0.0663 0.5342 0.9013 -0.2421 0.5439 0.6562 0.2446 0.6942 0.7246 0.2133 0.7055 0.7624 0.4925 0.5660 0.3842 0.3295 0.5749 0.5665 0.0329 0.5798 0.9547 -0.0997 0.5837 0.8644
HLA-B*18 1.6031 1.0311 0.1200 1.2442 1.0632 0.2419 0.7577 0.7706 0.3255 0.5275 0.7785 0.4981 0.2104 1.0204 0.8366 -0.0248 1.0310 0.9808 0.7611 1.2527 0.5435 0.4905 1.3329 0.7129 0.3187 0.7484 0.6702 0.0858 0.7566 0.9098 0.1416 0.9151 0.8771 -0.1548 0.9307 0.8679 -0.1014 1.2730 0.9365 -0.3067 1.2841 0.8112 -0.3139 0.8474 0.7111 -0.6112 0.8556 0.4750 -0.6072 1.0418 0.5600 -0.8106 1.0532 0.4415
HLA-B*18:01 1.6038 1.0312 0.1199 1.2451 1.0633 0.2416 0.7571 0.7705 0.3258 0.5270 0.7784 0.4984 0.2129 1.0202 0.8347 -0.0221 1.0308 0.9829 0.7621 1.2531 0.5431 0.4919 1.3333 0.7122 0.3209 0.7484 0.6681 0.0880 0.7566 0.9074 0.1442 0.9150 0.8748 -0.1520 0.9306 0.8703 -0.0995 1.2736 0.9377 -0.3048 1.2847 0.8125 -0.3136 0.8473 0.7113 -0.6108 0.8555 0.4753 -0.6044 1.0416 0.5617 -0.8076 1.0531 0.4431
HLA-B*27 -0.8416 0.9711 0.3861 -0.9934 0.9838 0.3126 0.5496 0.6542 0.4009 0.5459 0.6568 0.4059 -0.7354 0.7011 0.2942 -0.7647 0.7002 0.2748 -0.0054 0.8739 0.9951 -0.1440 0.8989 0.8727 0.7472 0.6330 0.2379 0.7615 0.6368 0.2317 -1.1237 0.6479 0.0829 -1.2332 0.6571 0.0606 -0.0919 1.0758 0.9319 -0.1448 1.0906 0.8944 1.2964 0.7551 0.0860 1.2832 0.7608 0.0916 -1.3803 0.6781 0.0418 -1.4688 0.6897 0.0332
HLA-B*27:05 -0.7715 0.9967 0.4389 -0.9404 1.0168 0.3550 0.5770 0.6720 0.3906 0.5782 0.6747 0.3914 -0.7131 0.7182 0.3207 -0.7401 0.7183 0.3029 0.1277 0.9247 0.8902 -0.0048 0.9464 0.9960 0.7638 0.6505 0.2403 0.7798 0.6540 0.2331 -1.1164 0.6679 0.0946 -1.2265 0.6778 0.0704 -0.0137 1.1212 0.9902 -0.0697 1.1322 0.9509 1.2864 0.7721 0.0957 1.2723 0.7770 0.1015 -1.4056 0.7039 0.0459 -1.4953 0.7158 0.0367
HLA-B*35 2.1954 0.7878 0.0053 2.0585 0.7954 0.0097 0.2648 0.5900 0.6536 0.1119 0.5972 0.8513 1.1997 0.6926 0.0832 1.0665 0.7106 0.1334 2.5542 0.9994 0.0106 2.4721 1.0207 0.0154 0.2876 0.5720 0.6151 0.0746 0.5837 0.8983 0.3416 0.5835 0.5583 0.1897 0.5976 0.7509 1.3087 1.2000 0.2755 1.2003 1.2116 0.3218 1.2576 0.9056 0.1649 1.0276 0.9155 0.2617 1.3403 0.7780 0.0849 1.2103 0.7773 0.1194
HLA-B*35:01 2.4092 0.8575 0.0050 2.2491 0.8601 0.0089 0.9941 0.6888 0.1489 0.8369 0.6977 0.2303 1.6427 0.8335 0.0487 1.5397 0.8558 0.0720 3.5923 1.3125 0.0062 3.5888 1.3591 0.0083 0.5359 0.6633 0.4192 0.2941 0.6749 0.6630 0.6074 0.6638 0.3601 0.4626 0.6815 0.4973 1.4249 1.1898 0.2311 1.3151 1.2052 0.2752 2.0080 1.1724 0.0868 1.7547 1.1744 0.1351 1.5127 0.8700 0.0821 1.3972 0.8720 0.1091
HLA-B*37 -0.7374 0.7619 0.3331 -0.2821 0.8051 0.7261 -0.3084 0.6221 0.6200 0.2439 0.6488 0.7070 -1.1191 0.8912 0.2092 -0.6606 0.9178 0.4716 -1.3465 0.7984 0.0917 -0.9568 0.8243 0.2457 -1.4081 0.5939 0.0177 -0.8180 0.6114 0.1809 -0.1745 0.6422 0.7859 0.3550 0.6685 0.5954 -2.2052 0.9173 0.0162 -1.9986 0.9518 0.0357 -1.4289 0.6333 0.0240 -0.8736 0.6537 0.1814 -0.0914 0.6790 0.8929 0.3508 0.7016 0.6170
HLA-B*37:01 -0.7370 0.7618 0.3333 -0.2817 0.8051 0.7264 -0.3085 0.6221 0.6200 0.2439 0.6488 0.7069 -1.1184 0.8911 0.2094 -0.6598 0.9176 0.4721 -1.3459 0.7984 0.0918 -0.9562 0.8243 0.2460 -1.4079 0.5939 0.0178 -0.8178 0.6114 0.1810 -0.1743 0.6421 0.7861 0.3552 0.6685 0.5951 -2.2048 0.9173 0.0162 -1.9982 0.9518 0.0358 -1.4288 0.6332 0.0241 -0.8734 0.6537 0.1815 -0.0909 0.6790 0.8935 0.3514 0.7016 0.6165
HLA-B*39 0.0086 0.7919 0.9913 -0.2866 0.8053 0.7219 0.5020 0.7730 0.5160 0.2462 0.7850 0.7538 1.1670 0.7244 0.1072 0.8580 0.7383 0.2452 0.5023 0.8011 0.5307 0.1964 0.8157 0.8097 0.4499 0.5919 0.4472 0.1400 0.6026 0.8163 2.0808 0.6566 0.0015 1.8660 0.6727 0.0055 0.0437 1.0223 0.9659 -0.1725 1.0301 0.8670 0.1310 0.6524 0.8409 -0.1632 0.6655 0.8063 0.1658 0.7166 0.8170 -0.0163 0.7314 0.9822
HLA-B*40 0.4242 0.7215 0.5566 0.3000 0.7429 0.6864 -0.0568 0.5778 0.9217 -0.4094 0.5940 0.4906 -0.9980 0.7512 0.1840 -1.3575 0.7698 0.0778 0.6125 0.8143 0.4520 0.5380 0.8545 0.5289 -0.0998 0.5602 0.8586 -0.4783 0.5731 0.4040 -0.6302 0.6413 0.3258 -0.9438 0.6535 0.1487 2.9386 1.8572 0.1136 3.0157 1.8771 0.1081 0.0541 0.7054 0.9389 -0.3421 0.7180 0.6337 -0.2336 0.6697 0.7272 -0.4430 0.6805 0.5150
HLA-B*40:01 0.5338 0.7232 0.4604 0.4185 0.7462 0.5749 0.2658 0.6088 0.6624 -0.0829 0.6239 0.8943 -0.7258 0.7842 0.3546 -1.0934 0.8010 0.1722 1.1277 0.8711 0.1955 1.0587 0.9084 0.2439 0.0349 0.5949 0.9532 -0.3485 0.6082 0.5666 -0.2930 0.6703 0.6620 -0.6369 0.6845 0.3522 8.6183 20.5072 0.6743 8.6503 20.3030 0.6701 0.0998 0.7152 0.8890 -0.3072 0.7309 0.6743 -0.1070 0.7186 0.8816 -0.3489 0.7316 0.6334
HLA-B*44 -0.1865 0.3954 0.6371 -0.3991 0.4068 0.3266 0.3904 0.3383 0.2484 0.2244 0.3453 0.5157 0.3974 0.3609 0.2709 0.2060 0.3710 0.5787 -0.8537 0.3973 0.0317 -1.1994 0.4185 0.0042 0.2756 0.3092 0.3728 0.0648 0.3167 0.8379 0.0873 0.3186 0.7841 -0.1020 0.3271 0.7552 -0.6561 0.4685 0.1613 -0.8748 0.4883 0.0732 0.2732 0.3594 0.4471 0.0551 0.3691 0.8814 0.1565 0.3455 0.6506 0.0081 0.3535 0.9817
HLA-B*44:02 0.0439 0.4849 0.9279 -0.0645 0.4939 0.8961 0.4200 0.4009 0.2948 0.2571 0.4071 0.5277 0.5595 0.4163 0.1789 0.3793 0.4259 0.3731 -1.0207 0.4861 0.0358 -1.2199 0.5030 0.0153 0.2897 0.3708 0.4346 0.1030 0.3773 0.7849 0.0302 0.3712 0.9353 -0.1551 0.3797 0.6829 -0.3860 0.5694 0.4978 -0.4875 0.5804 0.4009 -0.0188 0.4227 0.9644 -0.2286 0.4311 0.5959 0.3949 0.3984 0.3217 0.2685 0.4061 0.5085
HLA-B*44:03 -0.4453 0.6014 0.4591 -0.7668 0.6190 0.2154 0.3187 0.5927 0.5909 0.1779 0.6022 0.7676 -0.3284 0.6940 0.6360 -0.4808 0.7070 0.4964 -0.4596 0.5762 0.4251 -0.8570 0.5980 0.1518 0.2709 0.5174 0.6005 0.0648 0.5254 0.9018 0.2549 0.5449 0.6399 0.1270 0.5499 0.8174 -0.8828 0.7050 0.2105 -1.1260 0.7242 0.1200 0.6280 0.6047 0.2990 0.4526 0.6116 0.4592 -0.2594 0.5991 0.6650 -0.3743 0.6006 0.5332
HLA-B*45:01 -774.3203 1029.1792 0.4518 -772.4049 988.6552 0.4346 -6.5345 8.9152 0.4636 -6.4031 9.6632 0.5076 0.7609 1.6036 0.6351 1.4812 1.5944 0.3529 -1.2378 1.3488 0.3587 -0.6643 1.3964 0.6342 -1.0624 1.3334 0.4256 -0.5781 1.3434 0.6669 5.7606 12.4179 0.6427 6.4253 12.5322 0.6082 -357.6204 1115.9468 0.7486 -395.2113 1122.2534 0.7247 -1.2640 1.2982 0.3302 -0.8104 1.3082 0.5356 5.9832 18.1159 0.7412 6.6116 18.6327 0.7227
HLA-B*50 0.2256 1.3099 0.8632 1.2045 1.3634 0.3770 -0.0922 1.3434 0.9453 0.5222 1.3582 0.7006 11.9598 21.3270 0.5749 12.4769 21.4588 0.5609 -0.2731 1.2134 0.8219 0.5648 1.2585 0.6536 0.4948 1.4691 0.7363 1.1505 1.4714 0.4343 1.2022 1.2677 0.3430 1.6936 1.2888 0.1888 -1.4080 1.2701 0.2676 -1.0598 1.3180 0.4213 1.1581 1.9937 0.5613 1.7630 1.9707 0.3710 1.8012 1.3798 0.1917 2.1598 1.3879 0.1197
HLA-B*50:01 0.2396 1.3238 0.8563 1.2367 1.3770 0.3691 -0.1544 1.3783 0.9108 0.4664 1.3924 0.7376 12.2802 21.4470 0.5669 12.7983 21.5799 0.5531 -0.3202 1.2345 0.7954 0.5291 1.2795 0.6792 0.4831 1.4826 0.7445 1.1452 1.4851 0.4406 1.1999 1.2865 0.3510 1.6961 1.3079 0.1947 -1.5002 1.2991 0.2482 -1.1487 1.3466 0.3936 1.1629 2.0106 0.5630 1.7737 1.9878 0.3722 1.8083 1.3928 0.1942 2.1702 1.4011 0.1214
HLA-B*51 -0.4162 0.9231 0.6520 -0.7171 0.9319 0.4416 0.9918 0.9113 0.2764 0.7597 0.9127 0.4053 -0.6085 1.0383 0.5578 -0.6810 1.0328 0.5096 1.2542 0.8993 0.1631 0.9090 0.9270 0.3268 0.4183 0.8083 0.6048 0.1823 0.8158 0.8232 -0.2619 0.8212 0.7498 -0.3635 0.8271 0.6603 0.9242 1.0442 0.3761 0.7475 1.0706 0.4850 1.6398 1.1789 0.1643 1.3508 1.1856 0.2545 0.6333 0.9745 0.5158 0.4931 0.9754 0.6132
HLA-B*51:01 -0.4253 0.9387 0.6505 -0.7307 0.9473 0.4405 0.9955 0.9347 0.2869 0.7584 0.9363 0.4179 -0.6201 1.0609 0.5588 -0.6871 1.0545 0.5147 1.2574 0.9150 0.1694 0.9066 0.9433 0.3365 0.4426 0.8324 0.5949 0.2082 0.8400 0.8043 -0.2857 0.8472 0.7360 -0.3839 0.8534 0.6528 0.9307 1.0588 0.3794 0.7530 1.0859 0.4880 1.6693 1.1992 0.1639 1.3838 1.2068 0.2515 0.6635 1.0141 0.5129 0.5240 1.0148 0.6056
HLA-B*55:01 -1.7625 1.2726 0.1661 -1.9785 1.2945 0.1264 -1.0379 0.7963 0.1924 -1.2827 0.8127 0.1145 -0.2895 0.8627 0.7372 -0.6120 0.8761 0.4848 -1.8789 1.0506 0.0737 -2.1871 1.0709 0.0411 -0.8005 0.7811 0.3054 -1.1419 0.7914 0.1491 0.0995 0.8827 0.9103 -0.2127 0.8879 0.8106 -2.7929 1.3550 0.0393 -3.1048 1.3715 0.0236 -0.8935 0.8805 0.3102 -1.1748 0.8922 0.1879 0.6950 1.0949 0.5256 0.4260 1.0985 0.6982
HLA-B*57 -0.1450 0.4092 0.7232 0.4934 0.5015 0.3252 -0.4430 0.3536 0.2102 0.2497 0.4233 0.5553 -1.1515 0.4068 0.0046 -0.9107 0.4769 0.0562 -0.2194 0.3908 0.5744 0.3928 0.4758 0.4091 -0.2693 0.3202 0.4004 0.6806 0.3911 0.0818 -1.1106 0.3414 0.0011 -0.8592 0.4081 0.0353 0.2148 0.4940 0.6637 0.7110 0.5964 0.2332 -0.3371 0.3801 0.3752 0.4831 0.4476 0.2804 -0.9480 0.3635 0.0091 -0.7544 0.4344 0.0824
HLA-B*57:01 -0.2629 0.4246 0.5358 0.3894 0.5215 0.4552 -0.4698 0.3595 0.1913 0.2872 0.4417 0.5156 -1.2816 0.4180 0.0022 -1.0754 0.4985 0.0310 -0.2858 0.3962 0.4708 0.3614 0.4885 0.4594 -0.3390 0.3251 0.2971 0.6512 0.4022 0.1054 -1.0381 0.3446 0.0026 -0.7252 0.4184 0.0830 0.1477 0.4970 0.7664 0.6760 0.6084 0.2665 -0.4476 0.3822 0.2415 0.4151 0.4574 0.3641 -0.9040 0.3678 0.0140 -0.6807 0.4450 0.1261
HLA-C*01:02 -1.2310 1.1708 0.2931 -0.9998 1.2124 0.4096 2.7204 1.2231 0.0261 2.8887 1.2261 0.0185 1.3670 1.3755 0.3203 1.2828 1.3652 0.3474 -0.2131 1.0401 0.8376 0.0821 1.0717 0.9389 1.9240 1.1687 0.0997 1.9828 1.1702 0.0902 0.3082 0.9419 0.7435 0.2414 0.9538 0.8002 -0.9155 1.2233 0.4542 -0.7252 1.2369 0.5577 0.7124 1.0313 0.4897 0.7530 1.0471 0.4721 -0.3864 0.9268 0.6768 -0.4929 0.9370 0.5989
HLA-C*02:02 -1.7851 1.1806 0.1305 -2.1938 1.1965 0.0667 -1.0181 0.7571 0.1787 -1.2340 0.7597 0.1043 -1.1637 0.9863 0.2380 -1.3613 1.0074 0.1766 -0.9272 1.0895 0.3948 -1.3179 1.0988 0.2304 -0.3901 0.6881 0.5708 -0.5496 0.6986 0.4315 -1.8008 0.8597 0.0362 -2.0136 0.8802 0.0222 0.4557 1.4413 0.7519 0.1824 1.4363 0.8989 1.4584 1.0286 0.1562 1.2552 1.0386 0.2268 -2.2290 0.8890 0.0122 -2.3604 0.9068 0.0092
HLA-C*03 0.4238 0.4339 0.3287 0.3433 0.4490 0.4445 0.1483 0.3543 0.6756 -0.0675 0.3652 0.8534 -0.0456 0.4157 0.9127 -0.2778 0.4280 0.5163 -0.0705 0.4460 0.8745 -0.2511 0.4673 0.5910 -0.0356 0.3398 0.9166 -0.3103 0.3492 0.3742 0.1358 0.3638 0.7090 -0.0952 0.3739 0.7991 0.0972 0.5399 0.8571 0.0364 0.5595 0.9482 -0.2649 0.3888 0.4957 -0.5254 0.4010 0.1902 0.2034 0.3969 0.6083 0.0207 0.4064 0.9594
HLA-C*03:03 0.5387 0.6291 0.3918 0.3938 0.6400 0.5384 0.1123 0.5176 0.8283 -0.0417 0.5265 0.9369 -0.1780 0.5772 0.7578 -0.3256 0.5856 0.5782 -0.2409 0.6433 0.7081 -0.5035 0.6629 0.4475 0.1650 0.4973 0.7400 -0.0209 0.5053 0.9671 0.2303 0.5212 0.6586 0.0649 0.5269 0.9020 -0.0677 0.7811 0.9309 -0.1885 0.7972 0.8131 -0.3179 0.5508 0.5638 -0.5005 0.5635 0.3745 0.5080 0.5864 0.3863 0.3662 0.5903 0.5350
HLA-C*03:04 0.3814 0.5889 0.5172 0.3474 0.6096 0.5688 0.3893 0.5181 0.4524 0.1389 0.5303 0.7933 0.1539 0.6130 0.8018 -0.1500 0.6283 0.8113 0.3321 0.6135 0.5883 0.2485 0.6396 0.6976 -0.0689 0.4824 0.8864 -0.3764 0.4913 0.4437 0.0295 0.5352 0.9561 -0.2757 0.5472 0.6143 0.3362 0.7484 0.6533 0.3095 0.7645 0.6856 0.0520 0.5469 0.9243 -0.2210 0.5565 0.6913 -0.0298 0.5861 0.9595 -0.2753 0.5962 0.6442
HLA-C*04 1.2809 0.5480 0.0194 1.1165 0.5623 0.0471 0.3879 0.4629 0.4021 0.1647 0.4720 0.7271 1.2319 0.5746 0.0320 1.0891 0.5857 0.0629 1.9256 0.6929 0.0055 1.7995 0.7222 0.0127 0.1024 0.4316 0.8124 -0.1908 0.4426 0.6664 -0.0791 0.4872 0.8710 -0.2847 0.4991 0.5684 0.5382 0.7519 0.4742 0.3972 0.7732 0.6075 1.2132 0.6289 0.0537 0.9436 0.6378 0.1390 0.7279 0.6066 0.2301 0.5859 0.6093 0.3363
HLA-C*04:01 1.2807 0.5480 0.0194 1.1163 0.5622 0.0471 0.3895 0.4631 0.4003 0.1665 0.4721 0.7243 1.2322 0.5746 0.0320 1.0895 0.5856 0.0628 1.9256 0.6929 0.0055 1.7997 0.7222 0.0127 0.1028 0.4316 0.8117 -0.1903 0.4427 0.6673 -0.0791 0.4872 0.8710 -0.2847 0.4991 0.5684 0.5386 0.7519 0.4739 0.3977 0.7732 0.6070 1.2137 0.6289 0.0536 0.9442 0.6378 0.1388 0.7280 0.6066 0.2301 0.5860 0.6093 0.3362
HLA-C*05 -0.0558 0.4738 0.9063 -0.1354 0.4844 0.7799 0.4410 0.4023 0.2730 0.2649 0.4093 0.5175 0.3753 0.4272 0.3796 0.2026 0.4357 0.6419 -0.7644 0.4943 0.1220 -0.9047 0.5103 0.0762 0.5911 0.3911 0.1307 0.4091 0.3979 0.3039 0.2184 0.3765 0.5620 0.0539 0.3846 0.8885 -0.3393 0.5910 0.5659 -0.4126 0.5990 0.4910 0.0778 0.4354 0.8581 -0.1414 0.4445 0.7505 0.5108 0.4072 0.2097 0.3981 0.4140 0.3363
HLA-C*05:01 -0.0710 0.4761 0.8815 -0.1515 0.4868 0.7556 0.4484 0.4032 0.2660 0.2733 0.4102 0.5052 0.3858 0.4285 0.3679 0.2138 0.4370 0.6247 -0.7502 0.4964 0.1307 -0.8905 0.5126 0.0823 0.5867 0.3918 0.1343 0.4051 0.3986 0.3096 0.2132 0.3776 0.5722 0.0490 0.3856 0.8988 -0.3178 0.5938 0.5926 -0.3897 0.6023 0.5176 0.0718 0.4361 0.8692 -0.1468 0.4452 0.7416 0.5073 0.4081 0.2139 0.3947 0.4149 0.3414
HLA-C*06:02 -0.8325 0.3752 0.0265 N/A N/A N/A -1.0261 0.3171 0.0012 N/A N/A N/A -0.8542 0.3403 0.0121 N/A N/A N/A -0.9007 0.3776 0.0170 N/A N/A N/A -1.1982 0.2907 0.0000 N/A N/A N/A -0.9212 0.2966 0.0019 N/A N/A N/A -0.5041 0.4453 0.2576 N/A N/A N/A -1.1986 0.3444 0.0005 N/A N/A N/A -0.7242 0.3186 0.0230 N/A N/A N/A
HLA-C*07 0.0146 0.3196 0.9636 -0.2640 0.3473 0.4472 0.0406 0.2729 0.8817 -0.3054 0.2949 0.3003 -0.1987 0.3108 0.5226 -0.5315 0.3359 0.1136 0.0649 0.3403 0.8487 -0.2291 0.3688 0.5344 0.0544 0.2542 0.8304 -0.3805 0.2760 0.1681 0.0009 0.2708 0.9972 -0.3356 0.2924 0.2512 0.0712 0.4214 0.8658 -0.0764 0.4495 0.8650 -0.0747 0.3030 0.8053 -0.5374 0.3310 0.1045 0.2155 0.2978 0.4693 -0.0106 0.3197 0.9735
HLA-C*07:01 0.2009 0.3924 0.6087 -0.1094 0.4210 0.7950 -0.1022 0.3327 0.7588 -0.4907 0.3537 0.1654 0.0856 0.3873 0.8251 -0.2403 0.4090 0.5569 0.2219 0.4356 0.6105 -0.0998 0.4652 0.8302 -0.0030 0.3079 0.9921 -0.4478 0.3291 0.1736 0.0471 0.3457 0.8915 -0.3139 0.3672 0.3927 0.1211 0.5436 0.8237 -0.0059 0.5712 0.9917 -0.1119 0.3507 0.7497 -0.5846 0.3785 0.1225 0.3826 0.3871 0.3230 0.1428 0.4071 0.7258
HLA-C*07:02 0.2126 0.4711 0.6518 0.0912 0.4785 0.8488 0.2971 0.4219 0.4814 0.1686 0.4304 0.6952 -0.2210 0.4848 0.6485 -0.3825 0.4970 0.4415 0.3353 0.5186 0.5180 0.1646 0.5290 0.7557 0.1665 0.3914 0.6706 -0.0331 0.3978 0.9337 0.2003 0.3985 0.6153 0.0415 0.4076 0.9188 0.4810 0.6746 0.4758 0.3749 0.6791 0.5808 0.1278 0.5073 0.8011 -0.0278 0.5153 0.9569 -0.0384 0.4459 0.9314 -0.1509 0.4527 0.7388
HLA-C*07:04 -2.2720 1.2635 0.0721 -2.5154 1.2932 0.0518 1.1735 1.2154 0.3343 0.7987 1.2140 0.5106 -12473.9502 584170.5817 0.9830 -12627.0193 568437.6223 0.9823 -1.3436 1.0555 0.2030 -1.5198 1.0883 0.1626 0.5474 0.9170 0.5505 0.0499 0.9301 0.9572 -13126.1018 448867.3552 0.9767 -13285.2008 446453.5697 0.9763 -1.1875 1.1044 0.2823 -1.2586 1.1242 0.2629 0.5523 1.2946 0.6696 0.1272 1.3212 0.9233 -0.3163 1.0081 0.7537 -0.5123 1.0101 0.6120
HLA-C*08 -0.0677 0.8494 0.9365 -0.0387 0.8715 0.9646 -0.4667 0.7160 0.5146 -0.5919 0.7231 0.4130 -0.4014 0.9944 0.6865 -0.4943 0.9847 0.6157 90.5763 200.4101 0.6513 73.8402 197.9710 0.7092 1.1222 0.6911 0.1044 0.9413 0.6999 0.1786 0.6757 0.7627 0.3756 0.5302 0.7682 0.4901 7.8714 23.8518 0.7414 8.0838 23.6647 0.7327 0.8501 0.9218 0.3564 0.6926 0.9372 0.4599 0.2526 0.8845 0.7752 0.1080 0.8924 0.9037
HLA-C*08:02 -0.1346 0.8605 0.8757 -0.0855 0.8837 0.9229 -0.4885 0.7182 0.4964 -0.6084 0.7249 0.4013 -0.4121 0.9841 0.6754 -0.5037 0.9742 0.6051 281.3853 499.2105 0.5730 215.9621 492.0481 0.6607 1.0988 0.6902 0.1114 0.9218 0.6994 0.1875 0.7638 0.7727 0.3229 0.6156 0.7779 0.4288 8.6697 33.7311 0.7972 8.8603 33.4554 0.7911 0.8274 0.9204 0.3687 0.6743 0.9367 0.4716 0.2822 0.8867 0.7503 0.1305 0.8945 0.8840
HLA-C*12 1.0944 0.7352 0.1366 0.9052 0.7532 0.2295 0.8416 0.5584 0.1318 0.5226 0.5742 0.3627 1.6713 0.6076 0.0059 1.3807 0.6248 0.0271 0.9520 0.7391 0.1977 0.7349 0.7536 0.3295 1.0503 0.5228 0.0445 0.7013 0.5370 0.1915 2.0186 0.5795 0.0005 1.7448 0.5965 0.0034 -0.0327 0.8381 0.9689 -0.2183 0.8497 0.7973 0.8199 0.6337 0.1957 0.4714 0.6429 0.4634 0.6997 0.6698 0.2962 0.4533 0.6818 0.5061
HLA-C*12:03 1.3766 0.7728 0.0749 1.1924 0.7891 0.1308 0.5849 0.6070 0.3352 0.2749 0.6224 0.6588 1.4835 0.6368 0.0198 1.1819 0.6529 0.0703 0.9283 0.7482 0.2147 0.6994 0.7617 0.3585 0.8674 0.5390 0.1076 0.5260 0.5532 0.3417 1.8779 0.5850 0.0013 1.6010 0.6016 0.0078 -0.0859 0.8399 0.9185 -0.2767 0.8509 0.7450 0.7994 0.6409 0.2123 0.4655 0.6489 0.4731 0.6314 0.6780 0.3517 0.3925 0.6890 0.5689
HLA-C*15 0.6198 1.0515 0.5556 0.3992 1.0625 0.7071 0.7045 0.9076 0.4376 0.6530 0.9195 0.4776 0.2162 1.2151 0.8588 0.2144 1.2379 0.8625 1.2687 1.0290 0.2176 0.9279 1.0439 0.3741 0.1354 0.9149 0.8824 0.0609 0.9271 0.9476 0.1910 1.1617 0.8694 0.1669 1.1740 0.8870 0.3361 1.1408 0.7683 0.1884 1.1546 0.8704 0.3842 1.0548 0.7157 0.2760 1.0538 0.7934 -0.0852 1.1668 0.9418 -0.1076 1.1632 0.9263
HLA-C*15:02 0.6562 1.3968 0.6385 0.5839 1.4117 0.6792 -0.1389 1.1342 0.9025 -0.0400 1.1619 0.9725 -1.4208 1.6824 0.3984 -1.4751 1.7448 0.3979 0.5859 1.2074 0.6275 0.3769 1.2341 0.7601 -1.0648 1.2782 0.4048 -1.0173 1.3039 0.4353 -7.7305 38.3681 0.8403 -8.0029 45.1091 0.8592 -0.0960 1.2699 0.9397 -0.1603 1.2722 0.8997 -0.1862 1.1729 0.8738 -0.1023 1.1605 0.9298 -0.9658 1.4444 0.5037 -0.9382 1.4418 0.5152
HLA-C*16 -0.8160 0.8160 0.3173 -1.1533 0.8431 0.1713 0.2672 0.8436 0.7514 0.1665 0.8541 0.8454 -1.9009 1.2815 0.1380 -2.0202 1.3003 0.1203 -0.3803 0.6901 0.5816 -0.7286 0.7068 0.3026 0.8429 0.7279 0.2469 0.6840 0.7347 0.3518 0.6421 0.6477 0.3215 0.5375 0.6535 0.4107 -0.1672 0.8050 0.8355 -0.3355 0.8158 0.6809 1.1591 0.9265 0.2109 1.0175 0.9290 0.2734 0.1743 0.6934 0.8016 0.0639 0.6975 0.9270
HLA-C*16:01 -0.8657 0.8195 0.2908 -1.2053 0.8460 0.1543 0.6268 0.8669 0.4696 0.5666 0.8741 0.5168 -1.7182 1.2836 0.1807 -1.8388 1.3005 0.1574 -0.4736 0.6984 0.4977 -0.8209 0.7142 0.2504 1.0348 0.7561 0.1712 0.9093 0.7631 0.2334 0.6231 0.6551 0.3415 0.5237 0.6604 0.4278 -0.3218 0.8237 0.6960 -0.4874 0.8337 0.5588 1.3664 0.9549 0.1524 1.2378 0.9530 0.1940 0.0064 0.7099 0.9928 -0.0938 0.7126 0.8953
HLA-DPA1*01 -0.3392 0.3584 0.3439 -0.4029 0.3692 0.2751 -0.1711 0.3194 0.5923 -0.1985 0.3253 0.5418 -0.2888 0.3785 0.4454 -0.3254 0.3857 0.3989 0.0931 0.3680 0.8002 0.0048 0.3822 0.9900 -0.0978 0.2985 0.7431 -0.1583 0.3037 0.6021 -0.7154 0.3329 0.0316 -0.7744 0.3403 0.0229 -0.2809 0.4669 0.5474 -0.3785 0.4791 0.4295 -0.1929 0.3573 0.5893 -0.2372 0.3620 0.5122 -0.1542 0.3620 0.6702 -0.1896 0.3643 0.6028
HLA-DPA1*01:03 -0.3170 0.3562 0.3735 -0.3558 0.3664 0.3316 -0.2672 0.3149 0.3961 -0.2776 0.3203 0.3861 -0.3602 0.3742 0.3359 -0.3865 0.3811 0.3105 0.0621 0.3670 0.8655 -0.0060 0.3810 0.9875 -0.2099 0.2953 0.4771 -0.2514 0.2997 0.4016 -0.7961 0.3290 0.0155 -0.8400 0.3356 0.0123 -0.2919 0.4676 0.5324 -0.3753 0.4790 0.4333 -0.2731 0.3572 0.4445 -0.2962 0.3609 0.4118 -0.1832 0.3577 0.6086 -0.2056 0.3597 0.5675
HLA-DPA1*02 0.3407 0.3583 0.3417 0.4047 0.3691 0.2729 0.1680 0.3193 0.5988 0.1960 0.3252 0.5467 0.2896 0.3784 0.4440 0.3264 0.3857 0.3974 -0.0935 0.3679 0.7993 -0.0051 0.3821 0.9894 0.0939 0.2984 0.7529 0.1550 0.3036 0.6097 0.7147 0.3329 0.0318 0.7739 0.3403 0.0230 0.2797 0.4668 0.5491 0.3774 0.4790 0.4308 0.1939 0.3573 0.5874 0.2386 0.3619 0.5097 0.1536 0.3620 0.6713 0.1891 0.3643 0.6037
HLA-DPA1*02:01 0.3776 0.3899 0.3329 0.4438 0.4022 0.2699 0.3129 0.3590 0.3835 0.3152 0.3644 0.3870 0.3278 0.4256 0.4412 0.3763 0.4331 0.3849 -0.0742 0.4069 0.8552 0.0285 0.4232 0.9463 0.4067 0.3371 0.2276 0.4525 0.3423 0.1861 0.4710 0.3686 0.2013 0.5124 0.3764 0.1734 0.1549 0.5171 0.7646 0.2512 0.5294 0.6352 0.6171 0.4332 0.1544 0.6499 0.4381 0.1380 -0.3136 0.4061 0.4400 -0.2778 0.4085 0.4965
HLA-DPA1*02:02 0.3365 0.7967 0.6728 0.3811 0.8086 0.6375 -0.2617 0.6845 0.7022 -0.1850 0.6975 0.7908 0.3655 0.7433 0.6229 0.3518 0.7515 0.6397 0.0858 0.7295 0.9064 0.1248 0.7439 0.8667 -0.7996 0.6358 0.2085 -0.7128 0.6417 0.2667 1.3883 0.6812 0.0416 1.4202 0.6916 0.0400 0.8858 0.9661 0.3592 0.9385 0.9816 0.3390 -0.4538 0.6567 0.4896 -0.3593 0.6610 0.5868 1.5383 0.8016 0.0550 1.5554 0.8093 0.0546
HLA-DPB1*01:01 1.2168 0.6816 0.0742 1.1622 0.7047 0.0991 0.4103 0.5545 0.4593 0.2051 0.5681 0.7181 0.5056 0.6660 0.4477 0.4429 0.6740 0.5111 -0.0507 0.6726 0.9400 -0.1384 0.6958 0.8423 0.1952 0.5057 0.6995 -0.0402 0.5145 0.9378 1.0241 0.5580 0.0664 0.9643 0.5649 0.0878 0.4095 0.8806 0.6419 0.3854 0.8860 0.6636 0.6480 0.6602 0.3264 0.4804 0.6647 0.4699 0.6942 0.6254 0.2670 0.6121 0.6299 0.3312
HLA-DPB1*02 -0.5746 0.4470 0.1986 -0.6594 0.4589 0.1507 -0.1056 0.3540 0.7655 -0.1869 0.3584 0.6021 -0.0584 0.4231 0.8901 -0.1235 0.4280 0.7729 -0.0371 0.4425 0.9331 -0.0909 0.4606 0.8436 -0.2618 0.3276 0.4242 -0.3847 0.3324 0.2471 -0.1092 0.3460 0.7523 -0.1957 0.3489 0.5749 0.3276 0.5437 0.5468 0.3484 0.5570 0.5317 -0.1153 0.3950 0.7703 -0.2413 0.3999 0.5463 -0.4590 0.3726 0.2180 -0.5540 0.3754 0.1401
HLA-DPB1*02:01 -0.5884 0.4771 0.2175 -0.6693 0.4886 0.1707 -0.1474 0.3608 0.6828 -0.2104 0.3646 0.5639 -0.2007 0.4557 0.6597 -0.2723 0.4610 0.5547 0.0630 0.4682 0.8929 0.0156 0.4866 0.9744 -0.2814 0.3326 0.3975 -0.3844 0.3367 0.2537 -0.1491 0.3567 0.6760 -0.2406 0.3597 0.5036 0.5652 0.5951 0.3422 0.5945 0.6096 0.3294 -0.0572 0.4026 0.8870 -0.1629 0.4070 0.6890 -0.4810 0.3810 0.2068 -0.5753 0.3838 0.1339
HLA-DPB1*04 0.1179 0.2745 0.6675 0.1801 0.2817 0.5227 0.1210 0.2298 0.5986 0.2098 0.2341 0.3701 0.0080 0.2683 0.9761 0.0685 0.2732 0.8021 0.1393 0.2857 0.6259 0.1482 0.2945 0.6147 0.0565 0.2148 0.7926 0.1293 0.2187 0.5543 -0.3020 0.2353 0.1993 -0.2336 0.2391 0.3284 -0.2557 0.3485 0.4631 -0.2798 0.3546 0.4301 0.0067 0.2548 0.9790 0.1004 0.2597 0.6991 0.0200 0.2561 0.9377 0.0721 0.2583 0.7802
HLA-DPB1*04:01 0.3163 0.2703 0.2419 0.3879 0.2786 0.1638 0.1375 0.2251 0.5413 0.2139 0.2284 0.3489 -0.0935 0.2591 0.7181 -0.0353 0.2625 0.8931 0.1392 0.2801 0.6191 0.1479 0.2898 0.6099 -0.1071 0.2111 0.6119 -0.0380 0.2145 0.8592 -0.3008 0.2286 0.1883 -0.2330 0.2321 0.3154 0.0365 0.3399 0.9145 0.0248 0.3479 0.9432 -0.1782 0.2504 0.4766 -0.1049 0.2549 0.6806 -0.1174 0.2517 0.6410 -0.0736 0.2536 0.7716
HLA-DPB1*04:02 -0.6139 0.4867 0.2072 -0.6476 0.4969 0.1925 -0.0542 0.4108 0.8951 -0.0318 0.4145 0.9389 0.3236 0.4709 0.4919 0.3294 0.4771 0.4900 -0.0797 0.5379 0.8822 -0.1295 0.5540 0.8152 0.5977 0.4179 0.1526 0.6096 0.4247 0.1512 -0.1366 0.4578 0.7654 -0.1341 0.4631 0.7721 -1.2806 0.6654 0.0543 -1.3506 0.6731 0.0448 0.8262 0.5762 0.1516 0.8912 0.5841 0.1271 0.4824 0.5134 0.3474 0.4946 0.5143 0.3362
HLA-DPB1*05:01 -0.7692 0.9733 0.4293 -0.4196 0.9755 0.6671 -0.0236 1.0412 0.9820 0.2909 1.0538 0.7825 -1.3746 1.0542 0.1923 -1.2332 1.0803 0.2536 -0.2939 0.8777 0.7377 0.0464 0.8921 0.9585 -0.6882 0.8577 0.4224 -0.4308 0.8678 0.6196 0.4445 0.8003 0.5786 0.6739 0.8153 0.4085 0.9723 1.2554 0.4386 1.1442 1.2562 0.3624 -0.0223 0.9056 0.9804 0.2708 0.9169 0.7677 0.3838 0.7895 0.6269 0.4903 0.7991 0.5395
HLA-DPB1*10 0.1830 1.0372 0.8599 0.0055 1.0569 0.9958 1.0364 1.3284 0.4353 1.1238 1.3798 0.4154 2.7285 2.2360 0.2224 2.6621 2.2497 0.2367 -0.7641 1.1036 0.4887 -0.9715 1.1048 0.3792 2.6874 1.4326 0.0607 3.0063 1.4395 0.0368 1.2342 1.5201 0.4168 1.2215 1.5745 0.4379 0.4888 1.3851 0.7241 0.3984 1.3870 0.7739 14.6127 54.9102 0.7901 22.2756 64.6796 0.7305 61.2805 233.9200 0.7933 69.1649 247.9040 0.7802
HLA-DPB1*10:01 0.1829 1.0372 0.8600 0.0054 1.0569 0.9959 1.0364 1.3284 0.4353 1.1238 1.3798 0.4154 2.7285 2.2360 0.2224 2.6621 2.2497 0.2367 -0.7642 1.1036 0.4886 -0.9716 1.1048 0.3792 2.6874 1.4326 0.0607 3.0063 1.4395 0.0368 1.2342 1.5201 0.4168 1.2215 1.5745 0.4379 0.4885 1.3851 0.7243 0.3981 1.3870 0.7741 14.6131 54.9115 0.7901 22.2760 64.6796 0.7305 61.2805 233.9200 0.7933 69.1649 247.9040 0.7802
HLA-DPB1*11:01 0.9354 1.1484 0.4153 0.7808 1.1532 0.4983 -0.5692 1.0321 0.5813 -0.6585 1.0391 0.5263 -0.8964 1.6212 0.5803 -1.0968 1.6676 0.5107 0.1787 1.1549 0.8770 -0.1008 1.1682 0.9313 0.7013 0.8414 0.4045 0.5719 0.8486 0.5004 0.5533 0.9521 0.5612 0.5529 0.9805 0.5729 156.8692 12394.7795 0.9899 154.2851 12566.2219 0.9902 -1.0321 0.8714 0.2363 -1.1643 0.8873 0.1894 -1.6250 1.0083 0.1071 -1.6110 1.0132 0.1118
HLA-DPB1*13 1.6774 0.9367 0.0733 1.9292 0.9579 0.0440 0.8435 0.7907 0.2860 1.1059 0.7974 0.1655 0.9624 0.9990 0.3354 1.1824 1.0179 0.2454 0.0853 0.8324 0.9184 0.3706 0.8605 0.6667 0.1528 0.7528 0.8391 0.5198 0.7609 0.4945 0.5805 0.8812 0.5101 0.7787 0.8912 0.3822 -0.9431 0.9738 0.3328 -0.8307 0.9902 0.4016 0.2183 0.9629 0.8206 0.5296 0.9712 0.5855 -0.0338 1.2446 0.9783 0.1586 1.2537 0.8993
HLA-DPB1*13:01 1.6774 0.9367 0.0733 1.9292 0.9579 0.0440 0.8436 0.7907 0.2860 1.1059 0.7974 0.1655 0.9624 0.9990 0.3354 1.1824 1.0179 0.2454 0.0853 0.8324 0.9184 0.3706 0.8605 0.6667 0.1529 0.7528 0.8390 0.5199 0.7610 0.4944 0.5806 0.8812 0.5099 0.7789 0.8913 0.3821 -0.9431 0.9738 0.3328 -0.8307 0.9902 0.4016 0.2186 0.9630 0.8204 0.5299 0.9713 0.5853 -0.0332 1.2449 0.9787 0.1593 1.2540 0.8989
HLA-DPB1*17:01 -1.1776 1.0203 0.2484 -1.0488 1.0332 0.3100 -0.3751 1.0219 0.7136 -0.3090 1.0248 0.7631 -0.2877 1.7291 0.8679 -0.0893 1.7390 0.9591 0.2190 1.0699 0.8378 0.3112 1.0682 0.7708 -1.9696 1.2765 0.1228 -1.9465 1.2823 0.1290 -13.8808 457.7821 0.9758 -13.9547 455.3951 0.9756 12453.3418 575891.9005 0.9827 12254.8674 627918.3134 0.9844 13.1950 487.5802 0.9784 13.2373 477.5521 0.9779 -16.7636 652.7828 0.9795 -16.7965 652.0435 0.9794
HLA-DQA1*01 0.4100 0.3033 0.1765 0.3853 0.3136 0.2193 0.6771 0.2587 0.0089 0.5824 0.2630 0.0268 -0.4054 0.2891 0.1608 -0.5755 0.2984 0.0538 0.2819 0.3144 0.3699 0.2282 0.3295 0.4886 0.2297 0.2344 0.3271 0.0758 0.2402 0.7523 -0.1059 0.2493 0.6709 -0.2697 0.2561 0.2924 -0.1464 0.3871 0.7054 -0.2048 0.4011 0.6096 0.0825 0.2817 0.7696 -0.0654 0.2898 0.8214 -0.0556 0.2757 0.8403 -0.1727 0.2804 0.5379
HLA-DQA1*01:01 0.4426 0.3879 0.2539 0.5159 0.3976 0.1945 0.9491 0.3653 0.0094 0.8488 0.3686 0.0213 -0.1065 0.4257 0.8024 -0.2592 0.4331 0.5495 0.9114 0.4739 0.0545 0.9884 0.4860 0.0420 0.5772 0.3316 0.0817 0.4790 0.3367 0.1548 0.2039 0.3571 0.5680 0.0604 0.3662 0.8690 0.7844 0.6834 0.2510 0.8330 0.6944 0.2303 0.6030 0.3935 0.1254 0.5070 0.4006 0.2056 0.4304 0.3932 0.2737 0.3363 0.3981 0.3983
HLA-DQA1*01:02 -0.0142 0.3615 0.9687 -0.1343 0.3714 0.7176 -0.0496 0.3280 0.8798 -0.0909 0.3306 0.7834 -0.6606 0.3804 0.0825 -0.7386 0.3825 0.0535 0.0064 0.3912 0.9870 -0.1522 0.4082 0.7092 -0.3546 0.2995 0.2365 -0.4779 0.3034 0.1152 -0.2475 0.3228 0.4433 -0.3491 0.3262 0.2846 -0.4759 0.5050 0.3460 -0.5845 0.5129 0.2545 -0.4005 0.3619 0.2685 -0.5130 0.3668 0.1619 -0.1179 0.3709 0.7506 -0.1850 0.3731 0.6200
HLA-DQA1*01:03 0.6134 0.7319 0.4020 0.5385 0.7358 0.4642 0.9977 0.5203 0.0552 0.9345 0.5292 0.0774 0.0424 0.5308 0.9363 -0.0867 0.5420 0.8729 -0.5289 0.6925 0.4450 -0.6863 0.7086 0.3327 0.6211 0.4907 0.2056 0.5365 0.4979 0.2813 -0.4806 0.4912 0.3279 -0.5943 0.5001 0.2347 -0.5056 0.7376 0.4930 -0.5693 0.7518 0.4488 -0.0180 0.5852 0.9755 -0.0967 0.5913 0.8701 -0.9916 0.5212 0.0571 -1.1009 0.5305 0.0380
HLA-DQA1*02:01 -0.1833 0.3284 0.5767 0.1830 0.3808 0.6307 -0.7531 0.2833 0.0079 -0.4132 0.3262 0.2054 -0.3888 0.3116 0.2121 -0.0654 0.3604 0.8560 -0.2498 0.3254 0.4426 0.1211 0.3794 0.7496 -0.4888 0.2542 0.0545 0.0456 0.2975 0.8781 -0.2274 0.2700 0.3997 0.1681 0.3141 0.5926 0.4106 0.4020 0.3071 0.7944 0.4745 0.0941 -0.3037 0.2933 0.3005 0.2589 0.3485 0.4576 -0.5853 0.2940 0.0465 -0.4224 0.3409 0.2154
HLA-DQA1*03:01 -0.1563 0.3597 0.6639 -0.2428 0.3705 0.5121 -0.1150 0.2921 0.6938 -0.1850 0.2967 0.5329 0.5252 0.3475 0.1307 0.4564 0.3527 0.1956 -0.1851 0.3541 0.6012 -0.2617 0.3620 0.4697 0.0195 0.2777 0.9440 -0.0427 0.2795 0.8786 0.1429 0.2941 0.6270 0.0913 0.2978 0.7591 -0.6602 0.4152 0.1118 -0.7305 0.4219 0.0834 -0.2448 0.3208 0.4455 -0.3036 0.3234 0.3478 0.1476 0.3239 0.6487 0.1226 0.3273 0.7079
HLA-DQA1*04:01 -0.3824 1.0715 0.7212 -0.2131 1.0935 0.8455 -0.8802 1.0552 0.4042 -0.7937 1.0674 0.4572 0.8509 1.2553 0.4979 0.8832 1.2853 0.4920 1.1676 1.1338 0.3031 1.3285 1.1546 0.2499 0.0261 0.8520 0.9755 0.0667 0.8651 0.9385 0.6030 0.9491 0.5252 0.6739 0.9700 0.4872 1.4201 1.3061 0.2769 1.4164 1.2981 0.2752 -0.7736 1.1802 0.5121 -0.7358 1.1844 0.5345 0.2085 0.9733 0.8304 0.1634 0.9820 0.8679
HLA-DQA1*05:01 -0.0342 0.3743 0.9272 -0.3755 0.3994 0.3471 0.2612 0.3107 0.4005 -0.0616 0.3294 0.8517 0.6060 0.3514 0.0846 0.4055 0.3665 0.2685 0.1210 0.3933 0.7584 -0.1607 0.4217 0.7031 0.3384 0.2903 0.2438 -0.0286 0.3096 0.9264 0.2916 0.3112 0.3487 0.0413 0.3269 0.8994 0.4003 0.4916 0.4154 0.3342 0.5162 0.5174 0.6413 0.3566 0.0721 0.3000 0.3793 0.4289 0.6913 0.3430 0.0439 0.5186 0.3579 0.1474
HLA-DQB1*02 0.0856 0.3289 0.7947 -0.0051 0.3412 0.9881 0.0461 0.2762 0.8674 -0.0204 0.2831 0.9424 0.4318 0.3179 0.1744 0.4191 0.3245 0.1966 0.1277 0.3323 0.7008 0.0809 0.3441 0.8142 0.1524 0.2569 0.5530 0.0679 0.2603 0.7941 0.3179 0.2830 0.2613 0.2752 0.2866 0.3370 0.4917 0.4126 0.2334 0.5112 0.4170 0.2202 0.4802 0.3062 0.1169 0.3903 0.3060 0.2021 -0.0062 0.3112 0.9841 -0.0645 0.3114 0.8358
HLA-DQB1*02:01 0.0258 0.4462 0.9539 -0.2945 0.4805 0.5399 0.3610 0.3608 0.3170 -0.0297 0.3873 0.9388 0.3498 0.4454 0.4322 -0.0047 0.4715 0.9920 0.1795 0.4801 0.7086 -0.0781 0.5264 0.8820 0.5330 0.3364 0.1130 0.0953 0.3588 0.7906 0.1681 0.3989 0.6735 -0.2177 0.4224 0.6063 0.2831 0.6114 0.6433 0.2782 0.6469 0.6671 0.7433 0.4137 0.0724 0.3313 0.4396 0.4510 0.4402 0.4283 0.3041 0.1867 0.4506 0.6787
HLA-DQB1*02:02 0.0181 0.4227 0.9658 0.1476 0.4348 0.7342 -0.3026 0.3628 0.4043 -0.0243 0.3758 0.9484 0.3369 0.3921 0.3902 0.5720 0.4043 0.1571 0.0476 0.4099 0.9076 0.1603 0.4218 0.7040 -0.2298 0.3316 0.4883 0.0382 0.3434 0.9113 0.3976 0.3470 0.2519 0.6070 0.3564 0.0886 0.5575 0.5105 0.2748 0.6390 0.5175 0.2169 0.0925 0.3868 0.8109 0.3861 0.4033 0.3384 -0.3059 0.3779 0.4182 -0.1803 0.3844 0.6390
HLA-DQB1*03 -0.4128 0.2952 0.1620 -0.3672 0.3103 0.2366 -0.5956 0.2445 0.0149 -0.4829 0.2514 0.0548 -0.0016 0.2705 0.9953 0.1554 0.2811 0.5804 -0.4274 0.2950 0.1474 -0.3847 0.3148 0.2217 -0.3457 0.2242 0.1231 -0.1425 0.2319 0.5389 -0.2290 0.2386 0.3371 -0.0634 0.2464 0.7970 -0.3872 0.3594 0.2812 -0.3870 0.3777 0.3055 -0.3913 0.2645 0.1391 -0.2019 0.2735 0.4605 -0.0293 0.2639 0.9117 0.1252 0.2710 0.6441
HLA-DQB1*03:01 -0.5163 0.3729 0.1662 -0.7723 0.3849 0.0448 -0.1696 0.2968 0.5676 -0.3154 0.3023 0.2968 0.9276 0.3518 0.0084 0.8496 0.3557 0.0169 -0.4883 0.3696 0.1864 -0.7466 0.3833 0.0514 -0.0942 0.2777 0.7345 -0.2359 0.2851 0.4080 0.2420 0.2982 0.4169 0.1458 0.3038 0.6314 -0.7123 0.4372 0.1032 -0.9038 0.4518 0.0454 0.0165 0.3345 0.9607 -0.1305 0.3430 0.7037 0.7639 0.3447 0.0267 0.7101 0.3487 0.0417
HLA-DQB1*03:02 0.4454 0.5905 0.4507 0.6123 0.6127 0.3177 0.0005 0.4308 0.9991 0.0807 0.4345 0.8526 -0.0887 0.5246 0.8657 -0.1132 0.5297 0.8308 0.3164 0.5438 0.5607 0.4847 0.5613 0.3878 0.1557 0.4175 0.7092 0.2097 0.4179 0.6158 -0.0876 0.4475 0.8448 -0.0337 0.4500 0.9403 -0.0260 0.6236 0.9667 0.0128 0.6355 0.9839 -0.1611 0.4683 0.7308 -0.1023 0.4723 0.8285 -0.6223 0.4985 0.2119 -0.5876 0.4987 0.2387
HLA-DQB1*03:03 -0.3069 0.3924 0.4341 0.0269 0.4350 0.9508 -1.1231 0.3763 0.0028 -0.7933 0.4120 0.0542 -1.0365 0.4076 0.0110 -0.7747 0.4467 0.0829 -0.3760 0.3791 0.3214 -0.0744 0.4246 0.8609 -0.6749 0.3283 0.0398 -0.1086 0.3655 0.7664 -0.6689 0.3447 0.0523 -0.3200 0.3794 0.3990 0.1381 0.4731 0.7704 0.3779 0.5377 0.4822 -0.7468 0.3826 0.0509 -0.2470 0.4261 0.5622 -0.6180 0.3652 0.0906 -0.3483 0.4024 0.3868
HLA-DQB1*04 -0.3824 1.0715 0.7212 -0.2131 1.0935 0.8455 -0.7262 1.0503 0.4893 -0.6312 1.0624 0.5524 0.8509 1.2553 0.4979 0.8832 1.2853 0.4920 1.1676 1.1338 0.3031 1.3285 1.1546 0.2499 -0.0786 0.8438 0.9258 -0.0246 0.8567 0.9771 0.6030 0.9491 0.5252 0.6739 0.9700 0.4872 1.4201 1.3061 0.2769 1.4164 1.2981 0.2752 -0.8555 1.1737 0.4661 -0.8036 1.1782 0.4952 0.2085 0.9733 0.8304 0.1634 0.9820 0.8679
HLA-DQB1*04:02 -0.3824 1.0715 0.7212 -0.2131 1.0935 0.8455 -0.7313 1.0508 0.4865 -0.6365 1.0630 0.5493 0.8509 1.2553 0.4979 0.8832 1.2853 0.4920 1.1676 1.1338 0.3031 1.3285 1.1546 0.2499 -0.0762 0.8443 0.9280 -0.0227 0.8572 0.9789 0.6030 0.9491 0.5252 0.6739 0.9700 0.4872 1.4201 1.3061 0.2769 1.4164 1.2981 0.2752 -0.8544 1.1743 0.4669 -0.8028 1.1787 0.4958 0.2085 0.9733 0.8304 0.1634 0.9820 0.8679
HLA-DQB1*05 0.5047 0.3759 0.1794 0.5823 0.3853 0.1308 0.9218 0.3556 0.0095 0.8197 0.3587 0.0223 0.0387 0.4152 0.9258 -0.1115 0.4224 0.7918 1.1423 0.4658 0.0142 1.2233 0.4772 0.0104 0.4998 0.3223 0.1209 0.3919 0.3270 0.2308 0.2175 0.3490 0.5332 0.0718 0.3579 0.8410 1.0289 0.6667 0.1227 1.0657 0.6766 0.1152 0.6600 0.3915 0.0918 0.5538 0.3978 0.1638 0.4656 0.3848 0.2263 0.3737 0.3896 0.3375
HLA-DQB1*05:01 1.2065 0.4894 0.0137 1.2421 0.4939 0.0119 1.1329 0.4361 0.0094 1.0319 0.4386 0.0186 -0.1446 0.5084 0.7761 -0.2984 0.5165 0.5634 1.7234 0.6709 0.0102 1.7322 0.6785 0.0107 0.5902 0.3785 0.1189 0.5029 0.3823 0.1883 -0.1518 0.4008 0.7048 -0.3071 0.4103 0.4541 1.1146 0.7769 0.1513 1.1110 0.7809 0.1548 0.7684 0.4898 0.1167 0.6537 0.4924 0.1843 0.1586 0.4278 0.7107 0.0825 0.4320 0.8486
HLA-DQB1*05:03 -1.3118 0.7555 0.0825 -1.1993 0.7775 0.1230 0.0664 0.6658 0.9206 -0.0741 0.6876 0.9142 -0.1349 0.8014 0.8663 -0.2379 0.8219 0.7722 -1.0380 0.9130 0.2556 -0.9502 0.9584 0.3215 0.1862 0.6628 0.7788 -0.0232 0.6793 0.9727 1.2822 0.8765 0.1435 1.1788 0.8873 0.1840 -15.7751 805.9809 0.9844 -15.7890 802.4467 0.9843 0.3361 0.7313 0.6458 0.2365 0.7580 0.7550 1.3853 0.9415 0.1412 1.2526 0.9477 0.1863
HLA-DQB1*06 0.0694 0.3398 0.8383 -0.0314 0.3476 0.9280 0.2740 0.2936 0.3508 0.2126 0.2975 0.4748 -0.6006 0.3277 0.0668 -0.7288 0.3332 0.0287 -0.3745 0.3486 0.2827 -0.5510 0.3675 0.1337 -0.0429 0.2704 0.8739 -0.1704 0.2746 0.5349 -0.2954 0.2903 0.3089 -0.4249 0.2947 0.1494 -0.7234 0.4208 0.0856 -0.8456 0.4358 0.0523 -0.3648 0.3278 0.2658 -0.4804 0.3333 0.1495 -0.4538 0.3285 0.1672 -0.5557 0.3327 0.0948
HLA-DQB1*06:02 0.4530 0.4264 0.2882 0.3885 0.4349 0.3717 -0.0015 0.3832 0.9969 -0.0263 0.3876 0.9459 -0.6815 0.4362 0.1182 -0.7351 0.4386 0.0938 0.0494 0.4481 0.9122 -0.0776 0.4634 0.8671 -0.4942 0.3479 0.1555 -0.5871 0.3521 0.0955 -0.5021 0.3798 0.1861 -0.5865 0.3830 0.1257 -0.5684 0.6032 0.3461 -0.6573 0.6074 0.2792 -0.6292 0.4190 0.1332 -0.7066 0.4213 0.0935 -0.4038 0.4440 0.3630 -0.4551 0.4458 0.3073
HLA-DQB1*06:03 0.5645 0.7015 0.4210 0.5095 0.7069 0.4711 0.7868 0.5212 0.1311 0.7438 0.5291 0.1598 -0.2887 0.5404 0.5932 -0.4232 0.5521 0.4433 -0.5781 0.6751 0.3918 -0.7217 0.6931 0.2978 0.4857 0.4979 0.3293 0.4153 0.5047 0.4106 -0.6201 0.4979 0.2130 -0.7258 0.5074 0.1526 -0.5545 0.7221 0.4426 -0.6060 0.7377 0.4114 0.0113 0.5914 0.9848 -0.0485 0.5968 0.9352 -1.0076 0.5278 0.0563 -1.0973 0.5375 0.0412
HLA-DQB1*06:04 -1.0306 1.2768 0.4196 -1.1706 1.2937 0.3655 -0.2100 0.9762 0.8297 -0.2675 0.9906 0.7871 -0.5635 1.0400 0.5879 -0.6432 1.0497 0.5401 -1.6850 1.0573 0.1110 -1.8845 1.1212 0.0928 0.6388 0.8015 0.4254 0.5215 0.8127 0.5210 0.4404 0.8944 0.6224 0.3335 0.8998 0.7109 -1.5679 1.1405 0.1692 -1.6402 1.1566 0.1561 0.0554 0.9776 0.9548 -0.0722 0.9862 0.9416 0.2965 1.0019 0.7673 0.2213 1.0064 0.8259
HLA-DRB1*01 0.9785 0.4959 0.0485 0.9933 0.5060 0.0497 1.2343 0.4583 0.0071 1.1174 0.4614 0.0154 -0.1209 0.5233 0.8173 -0.3020 0.5332 0.5712 1.5443 0.6196 0.0127 1.5785 0.6347 0.0129 0.7245 0.3998 0.0699 0.5955 0.4070 0.1434 -0.0855 0.4072 0.8337 -0.2749 0.4173 0.5100 0.7779 0.6973 0.2646 0.7753 0.7083 0.2737 0.6924 0.5141 0.1780 0.5341 0.5232 0.3073 -0.0174 0.4348 0.9681 -0.1366 0.4400 0.7562
HLA-DRB1*01:01 1.5526 0.6240 0.0128 1.6815 0.6460 0.0092 1.2933 0.5636 0.0217 1.1811 0.5693 0.0380 -0.3139 0.6086 0.6060 -0.4817 0.6188 0.4364 1.9979 0.8984 0.0262 2.0997 0.9144 0.0217 0.4435 0.4710 0.3464 0.3182 0.4781 0.5057 -0.4856 0.4755 0.3071 -0.6902 0.4871 0.1565 1.8586 1.4135 0.1885 1.8762 1.4278 0.1888 0.2886 0.5787 0.6180 0.1438 0.5845 0.8056 -0.2888 0.4975 0.5616 -0.4247 0.5053 0.4006
HLA-DRB1*01:03 2.1035 1.5271 0.1684 1.9383 1.5359 0.2070 47.9791 44.0642 0.2762 42.6779 44.2340 0.3346 0.8802 1.7939 0.6237 0.7918 1.8230 0.6640 1.8161 1.4084 0.1972 1.5652 1.4080 0.2663 2.6329 1.4361 0.0667 2.4856 1.4502 0.0865 1.2382 1.2948 0.3389 1.1952 1.3164 0.3639 0.1246 1.3022 0.9238 -0.0293 1.3064 0.9821 3.8057 1.9570 0.0518 3.5902 1.9512 0.0658 0.7443 1.2138 0.5397 0.7226 1.2173 0.5528
HLA-DRB1*03 0.0947 0.4451 0.8316 -0.2288 0.4775 0.6318 0.3445 0.3659 0.3465 -0.0385 0.3912 0.9216 0.3512 0.4411 0.4259 0.0234 0.4652 0.9598 0.1654 0.4793 0.7300 -0.1102 0.5236 0.8333 0.4401 0.3394 0.1948 -0.0127 0.3623 0.9721 0.1473 0.3959 0.7098 -0.2333 0.4188 0.5774 0.2632 0.6099 0.6661 0.2369 0.6423 0.7122 0.7407 0.4156 0.0747 0.3176 0.4411 0.4716 0.2984 0.4218 0.4793 0.0301 0.4440 0.9460
HLA-DRB1*03:01 0.0942 0.4451 0.8323 -0.2293 0.4776 0.6311 0.3447 0.3659 0.3462 -0.0382 0.3912 0.9222 0.3518 0.4411 0.4251 0.0241 0.4652 0.9586 0.1649 0.4793 0.7309 -0.1108 0.5236 0.8324 0.4403 0.3395 0.1946 -0.0123 0.3624 0.9729 0.1473 0.3960 0.7099 -0.2333 0.4188 0.5775 0.2628 0.6099 0.6666 0.2365 0.6423 0.7127 0.7407 0.4156 0.0747 0.3176 0.4411 0.4716 0.2978 0.4218 0.4802 0.0295 0.4440 0.9471
HLA-DRB1*04 -0.1680 0.3724 0.6518 -0.2195 0.3830 0.5667 -0.0800 0.2981 0.7883 -0.1419 0.3026 0.6391 0.5678 0.3565 0.1112 0.5074 0.3620 0.1611 -0.2531 0.3640 0.4868 -0.2892 0.3714 0.4362 0.1139 0.2818 0.6860 0.0620 0.2836 0.8270 0.0570 0.2965 0.8476 0.0127 0.3003 0.9663 -0.8423 0.4279 0.0490 -0.8737 0.4332 0.0437 -0.1488 0.3256 0.6477 -0.2007 0.3279 0.5405 0.1068 0.3283 0.7448 0.0905 0.3311 0.7846
HLA-DRB1*04:01 -0.3895 0.4315 0.3667 -0.3585 0.4423 0.4177 -0.2131 0.3507 0.5434 -0.2332 0.3545 0.5106 0.8491 0.4185 0.0425 0.8322 0.4213 0.0483 -0.6648 0.4141 0.1084 -0.6702 0.4226 0.1128 0.0011 0.3186 0.9973 0.0046 0.3216 0.9886 0.2848 0.3412 0.4039 0.2771 0.3453 0.4222 -1.0764 0.4799 0.0249 -1.0828 0.4868 0.0261 0.0591 0.3679 0.8723 0.0724 0.3722 0.8458 0.0556 0.3768 0.8827 0.0632 0.3802 0.8680
HLA-DRB1*04:07 -0.0605 1.4886 0.9676 -0.5252 1.5052 0.7272 -0.3515 1.0059 0.7268 -0.5675 1.0075 0.5733 3.2453 2.4334 0.1823 2.8724 2.3874 0.2289 0.6060 1.5620 0.6981 0.1111 1.6205 0.9453 -0.6969 1.0007 0.4862 -0.9357 1.0271 0.3623 -0.8958 1.4188 0.5278 -1.1994 1.4194 0.3981 -0.4047 1.4872 0.7855 -0.7244 1.5229 0.6343 -1.0540 1.2810 0.4106 -1.3101 1.3078 0.3165 1.6622 1.4587 0.2545 1.4928 1.4713 0.3103
HLA-DRB1*07 -0.2256 0.3305 0.4949 0.1326 0.3835 0.7296 -0.7409 0.2831 0.0089 -0.3959 0.3263 0.2250 -0.3871 0.3116 0.2140 -0.0633 0.3602 0.8604 -0.2604 0.3275 0.4266 0.1149 0.3824 0.7638 -0.5001 0.2548 0.0497 0.0324 0.2984 0.9135 -0.2228 0.2699 0.4091 0.1734 0.3139 0.5808 0.4073 0.4042 0.3136 0.7956 0.4773 0.0956 -0.3084 0.2943 0.2946 0.2558 0.3499 0.4647 -0.5877 0.2939 0.0455 -0.4255 0.3406 0.2115
HLA-DRB1*07:01 -0.2257 0.3305 0.4948 0.1325 0.3835 0.7297 -0.7408 0.2831 0.0089 -0.3958 0.3263 0.2251 -0.3871 0.3116 0.2141 -0.0633 0.3602 0.8606 -0.2604 0.3275 0.4266 0.1150 0.3824 0.7637 -0.5001 0.2548 0.0497 0.0325 0.2984 0.9134 -0.2228 0.2699 0.4091 0.1734 0.3139 0.5808 0.4074 0.4042 0.3135 0.7957 0.4774 0.0956 -0.3084 0.2943 0.2947 0.2559 0.3499 0.4646 -0.5876 0.2939 0.0456 -0.4254 0.3406 0.2116
HLA-DRB1*08 -0.8789 0.9258 0.3425 -0.8602 0.9473 0.3638 -1.4985 1.0110 0.1383 -1.5484 1.0183 0.1284 0.5351 1.0893 0.6233 0.4726 1.1039 0.6686 0.5984 0.9234 0.5170 0.6459 0.9425 0.4932 -0.4657 0.7857 0.5534 -0.5535 0.7968 0.4872 0.4344 0.8724 0.6186 0.4152 0.8884 0.6403 0.8259 1.0576 0.4348 0.8115 1.0640 0.4456 -0.6463 1.0380 0.5335 -0.7321 1.0421 0.4824 0.2706 0.8931 0.7619 0.1715 0.8976 0.8485
HLA-DRB1*08:01 -0.1453 1.1097 0.8958 0.1547 1.1353 0.8916 -0.8698 1.0594 0.4117 -0.7839 1.0710 0.4642 0.6505 1.2993 0.6166 0.6908 1.3290 0.6032 1.0009 1.1697 0.3922 1.2141 1.1848 0.3055 0.0184 0.8568 0.9829 0.0574 0.8699 0.9474 0.1969 1.0152 0.8462 0.2927 1.0293 0.7761 1.3362 1.3301 0.3151 1.3490 1.3190 0.3064 -0.7874 1.1843 0.5061 -0.7535 1.1893 0.5264 0.1411 1.0043 0.8883 0.1140 1.0121 0.9103
HLA-DRB1*09:01 -0.1553 1.2978 0.9048 -0.3997 1.3308 0.7639 -0.9897 1.2419 0.4255 -1.0393 1.2467 0.4045 0.7680 1.3430 0.5674 0.5570 1.3537 0.6807 0.6037 1.3017 0.6428 0.2278 1.3250 0.8635 -1.7810 1.5064 0.2371 -1.7893 1.4914 0.2303 0.9353 1.1285 0.4072 0.7333 1.1382 0.5194 1.1007 1.4664 0.4529 0.8010 1.4820 0.5889 -2.5337 1.9072 0.1840 -2.5483 1.8723 0.1735 0.5329 1.1508 0.6433 0.3709 1.1639 0.7500
HLA-DRB1*11 -0.2028 0.6925 0.7696 -0.4292 0.7003 0.5399 0.0460 0.6418 0.9429 0.0307 0.6436 0.9620 0.4887 0.6032 0.4179 0.4437 0.6095 0.4666 0.3963 0.7411 0.5928 0.1653 0.7517 0.8259 -0.3620 0.5801 0.5327 -0.4017 0.5896 0.4956 0.1221 0.5566 0.8263 0.0506 0.5634 0.9284 1.0056 1.0258 0.3269 0.8643 1.0346 0.4035 0.2137 0.7365 0.7717 0.1271 0.7473 0.8650 1.3034 0.6656 0.0502 1.2519 0.6698 0.0616
HLA-DRB1*12:01 0.7377 0.9849 0.4538 0.5398 1.0402 0.6038 -0.1197 0.9523 0.8999 -0.3573 0.9896 0.7181 1.5846 1.1138 0.1548 1.6367 1.1468 0.1535 -0.5047 0.9697 0.6027 -0.7229 1.0051 0.4720 -0.3009 0.9015 0.7385 -0.6378 0.9117 0.4841 -0.3176 0.8237 0.6998 -0.3454 0.8411 0.6813 -0.0512 1.5375 0.9735 -0.3166 1.5144 0.8344 0.1369 1.0900 0.9000 -0.1037 1.0906 0.9243 -0.3611 1.1359 0.7506 -0.4077 1.1471 0.7223
HLA-DRB1*13 -0.3809 0.5354 0.4768 -0.5422 0.5451 0.3199 0.2150 0.4295 0.6167 0.1365 0.4364 0.7544 -0.3926 0.4666 0.4001 -0.5412 0.4764 0.2560 -1.1253 0.5288 0.0333 -1.3764 0.5525 0.0127 0.2633 0.3938 0.5038 0.1452 0.3995 0.7163 -0.3200 0.4207 0.4469 -0.4466 0.4283 0.2971 -0.9880 0.5801 0.0886 -1.1225 0.5965 0.0598 -0.0780 0.4680 0.8676 -0.1722 0.4736 0.7162 -0.4515 0.4523 0.3182 -0.5559 0.4578 0.2247
HLA-DRB1*13:01 0.7823 0.7549 0.3001 0.7159 0.7578 0.3448 0.7178 0.5379 0.1821 0.6924 0.5464 0.2051 -0.2342 0.5490 0.6697 -0.3581 0.5607 0.5231 -0.7249 0.7085 0.3063 -0.8768 0.7215 0.2243 0.3807 0.5024 0.4486 0.3260 0.5091 0.5220 -0.7697 0.5069 0.1289 -0.8723 0.5159 0.0909 -0.6060 0.7457 0.4164 -0.6712 0.7569 0.3752 -0.0414 0.5940 0.9444 -0.0831 0.5990 0.8896 -1.1665 0.5348 0.0292 -1.2582 0.5440 0.0207
HLA-DRB1*13:02 -2.0697 0.9305 0.0261 -2.3607 0.9354 0.0116 -0.9970 0.7994 0.2123 -1.1489 0.8143 0.1583 -0.6688 0.9428 0.4781 -0.8112 0.9510 0.3937 -1.3512 0.8732 0.1217 -1.5862 0.9171 0.0837 0.0183 0.6678 0.9781 -0.1821 0.6740 0.7870 0.4180 0.7971 0.6000 0.2583 0.8031 0.7477 -1.3225 1.0618 0.2130 -1.4483 1.0754 0.1781 -0.1466 0.7945 0.8537 -0.3121 0.7994 0.6962 0.5011 0.8810 0.5695 0.3871 0.8841 0.6615
HLA-DRB1*14 -1.3547 0.7611 0.0751 -1.2449 0.7837 0.1122 0.0481 0.6695 0.9428 -0.1054 0.6918 0.8788 -0.1730 0.8045 0.8297 -0.2913 0.8243 0.7238 -1.1896 0.9395 0.2054 -1.1113 0.9858 0.2596 0.1882 0.6633 0.7766 -0.0347 0.6807 0.9593 1.3431 0.9046 0.1376 1.2273 0.9152 0.1800 -13049.2503 526727.3602 0.9802 -13002.4989 518437.2586 0.9800 0.2553 0.7364 0.7288 0.1355 0.7638 0.8591 1.4612 0.9602 0.1281 1.3219 0.9665 0.1714
HLA-DRB1*14:01 -1.4844 0.8192 0.0700 -1.4248 0.8512 0.0941 0.0506 0.7491 0.9462 -0.0752 0.7759 0.9228 -0.4748 0.8969 0.5965 -0.6579 0.9141 0.4717 -1.9561 1.1288 0.0831 -1.9597 1.1911 0.0999 -0.1842 0.7396 0.8033 -0.4090 0.7588 0.5899 1.5501 1.1543 0.1793 1.3892 1.1688 0.2346 -1896.2642 117917.3077 0.9872 -1890.2362 117333.7475 0.9871 -0.2962 0.8020 0.7119 -0.4083 0.8341 0.6245 1.8053 1.3289 0.1743 1.6410 1.3440 0.2221
HLA-DRB1*15 0.2971 0.4113 0.4700 0.2170 0.4216 0.6068 0.2967 0.3631 0.4138 0.2449 0.3682 0.5059 -0.4824 0.4168 0.2472 -0.5528 0.4200 0.1881 0.2144 0.4357 0.6227 0.0860 0.4525 0.8492 -0.2187 0.3412 0.5215 -0.3257 0.3453 0.3456 -0.2080 0.3717 0.5758 -0.3000 0.3756 0.4244 -0.4259 0.5928 0.4725 -0.5223 0.5974 0.3820 -0.6104 0.4142 0.1405 -0.7059 0.4172 0.0907 -0.2150 0.4409 0.6258 -0.2763 0.4428 0.5327
HLA-DRB1*15:01 0.3273 0.4175 0.4330 0.2604 0.4270 0.5419 0.0974 0.3706 0.7927 0.0666 0.3755 0.8593 -0.6296 0.4316 0.1446 -0.6846 0.4340 0.1147 0.1328 0.4401 0.7629 0.0104 0.4558 0.9818 -0.3554 0.3460 0.3044 -0.4484 0.3496 0.1996 -0.3604 0.3787 0.3413 -0.4342 0.3819 0.2555 -0.4794 0.5994 0.4239 -0.5686 0.6033 0.3460 -0.6324 0.4169 0.1293 -0.7099 0.4190 0.0902 -0.2448 0.4461 0.5832 -0.2919 0.4472 0.5139
Full drug × HLA allele interaction test results for all HLA alleles
Conditional on HLA-C*06:02 Full model drug × HLA allele interaction Conditional on HLA-C*06:02 Full model drug × HLA allele interactionConditional on HLA-C*06:02 Full model drug × HLA allele interaction
"Full model": based on full GxE model including clinical covariates and interaction terms; “Conditional on HLA-C*06:02”: based on a model that also includes HLA-C*06:02 main 
effect and interaction terms. In each case effect size (beta), standard error and p-value of HLA allele dosage × Drug interaction term are reported.
Conditional on HLA-C*06:02 Full model drug × HLA allele interaction Conditional on HLA-C*06:02 Full model drug × HLA allele interactionFull model drug × HLA allele interaction Conditional on HLA-C*06:02 Full model drug × HLA allele interaction Conditional on HLA-C*06:02 Full model drug × HLA allele interaction
PASI75 response PASI90 response PASI100 response
3m 6m 12m 3m 6m 12m
Conditional on HLA-C*06:02Conditional on HLA-C*06:02 Full model drug × HLA allele interaction
3m 6m 12m
